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CHARACTERIZING THE EFFECTS OF HIGH-INTENSITY EXERCISE ON
BALANCE AND GAIT UNDER DUAL-TASK CONDITIONS IN
PARKINSON’S DISEASE
ELISE IVA BARON
ABSTRACT
Parkinson’s disease (PD) is a neurodegenerative disorder, characterized by four
cardinal motor symptoms including bradykinesia, tremor, rigidity, and postural
instability, and non-motor symptoms including cognitive impairment. Daily activities,
such as walking and maintaining balance, are impacted due to impairments in motor
function, and are further exacerbated with the addition of cognitive loading, or dualtasking (DT). High-intensity exercise has demonstrated centrally-mediated improvements
of PD symptoms, with additional positive effects on overall health.
The goal of this project was to identify changes in dynamic balance recovery and
gait function under conditions with and without increased cognitive load after a highintensity exercise intervention in a PD population. Participants included people with PD
who completed an eight-week cycling intervention (PDE), people with Parkinson’s
disease who did not complete the intervention (PDC), and healthy age-matched controls
(HC), with 14 subjects per group. In Aim 1, while participants underwent a series of
destabilizing balance tests, the time taken to regain balance and the center of pressure
movement during balance recovery were measured. The PDE group demonstrated greater
improvement in balance recovery after exercise compared with the PDC group. In Aim 2,
participants completed a series of gait and cognitive tasks, both separately and
concurrently. Outcome measures included spatiotemporal and kinematic gait parameters
vi

of the lower and upper extremities. The PDE group demonstrated significant
improvement in gait measures and DT abilities compared to PDC, while no changes were
found in cognitive function for any group.
The standard clinical methods of measuring motor function can be subjective, and
may not capture subtle motor characteristics. Force plate and motion-capture
technologies can provide detailed, objective outcome data, therefore improving the
understanding of how exercise affects motor symptoms of Parkinson’s disease. The
Motek Computer Assisted Rehabilitation Environment (CAREN) system at the Cleveland
Clinic was used to create the testing environment and for data collection.
These results of this project suggest global changes in motor function
demonstrated by changes in balance recovery and lower and upper extremity gait
function. Quantitative gait analysis has shown to be an important metric in assessing
effectiveness of an exercise intervention in PD.
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CHAPTER I
INTRODUCTION
1.1 Parkinson’s Disease
James Parkinson identified a movement disorder marked by flexed posture,
resting tremor and shuffling gait. He termed this disorder “shaking palsy,” and published
his findings in 1817. This disorder was later named after him, and research on
Parkinson’s disease (PD) has continued since [3]. It was not until nearly a century later,
in 1914 when Frederic Lewy discovered cytoplasmic inclusions in the brains of people
with PD (now known as Lewy bodies) [4] and in 1919 when Konstantin Tretiakoff
discovered lesions in the substantia nigra [5] that we began to understand the cause of
Parkinsonian symptoms. In 1959, Arvid Carlsson published his findings that dopamine,
not serotonin as previously thought, was deficient in the brains of Parkinson’s patients
[6]. These neurological discoveries are the foundation for what we know about
Parkinson’s disease today.
With the advancement of scientific discoveries, the description of Parkinson’s
disease has expanded to include additional symptoms and greater pathological detail (See
Table 1). Symptoms are categorized as motor or non-motor, and patients exhibit some,
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but not necessarily all of these symptoms. Parkinson’s disease is unique to each
diagnosed individual, and can vary greatly.
Table I – Parkinson’s disease symptoms
Motor/Nonmotor
Motor

Symptom

Description

Reference

Resting tremor

Tremor of a limb when not in action

[3]

Motor

Rigidity

Stiffness of movement

[3]

Motor

Bradykinesia

Slowness of movement

[3]

Motor

Stooped posture

Flexion of torso and/or limbs

[3]

Motor

Postural response issues

Improper balance reactions

[7]

Motor

Freezing of gait

Inability to step, usually at gait initiation

[3]

Motor

Festinating gait

Short, quick steps

[8]

Motor

Masked face

Lack of facial expression

[8]

Motor

Postural instability

Balance issues

[8]

Non-motor

Non-motor

Sensory

Non-motor

Autonomic function issues

Non-motor

Sleep issues

Non-motor

Fatigue

Depression, fear, anxiety, passivity,
dependence, apathy
Bradyphrenia (slowed thought process),
dementia
Olfactory loss, numbness, burning
sensation, restless less syndrome, akathesia
(restlessness)
Hypotension, bladder problems,
constipation, sexual dysfunction, seborrhea,
dermatitis, sweating
REM sleep behavior disorder, excessive
daytime sleepiness, altered sleep-wake
cycle
Tiredness

[3]

Non-motor

Personality and behavior
changes
Cognition and mental

[3]
[3], [9]

[3]

[3]

[3]

The four cardinal symptoms of Parkinson’s disease include resting tremor,
bradykinesia, rigidity and postural instability [10]. Although disease presentation and
progression is unique to every patient, these symptoms are typically the first to appear
[3]. Unlike resting tremor - which dissipates during active movements - bradykinesia,
rigidity, and postural stability deficits permeate daily activities, impacting quality of life.
In Parkinsonian gait, for example, rigidity and bradykinesia often manifest as decreased
walking speed [11]–[19], and postural abnormalities [10]. Deficits in postural stability
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may induce compensatory tactics during gait such as increased double leg support time to
increase stability during gait [12], [16], [17], [20].
As the disease progresses and symptoms worsen, the consequences of the disease
increase. Indirect costs, such as productivity loss, or early retirement accounts for
approximately $1.7 billion in reduced national productivity [21]. The estimated
prevalence of PD in the /United States is 0.3% in the population overall, with an
increased rate of 1-2% in those 65 years of age and older, and 4-5% for those 85 and
older. The financial burden of this disease can be estimated at $14.0 billion a year in the
United States [21]. The incidence rate increases with age, and most rapidly after 60 years
of age [22]. As the number of people 65 and older continues to increase, costs can be
expected to increase as well [23].
Although Parkinson’s disease has no cure, treatments are available. Targeting
brain function directly, dopamine replacement drugs and deep brain stimulation alleviate
motor symptoms [3], [24]; however, side effects, such as dyskinesia (involuntary
movements) [3], and risks of invasive surgery [24] accompany these treatment options.
High-intensity aerobic exercise also aims to target changes in the brain, but is associated
with lower risk and side effects. Animal models have shown significant symptom
improvement from high-intensity exercise, and highlights several possible mechanisms
for these results [25]–[27]. Human studies have also shown significant improvements in
various measures, and are continuing to provide new information concerning the effects
of different exercise parameters [28]–[31].
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1.1.1 Parkinson’s Disease Neuropathology
In a normal healthy brain, the basal ganglia, located at the base of the forebrain,
are a collection of nuclei that are involved with various functions, voluntary movement
control, procedural learning, cognition and routine behaviors [32]. The putamen, caudate
nucleus, nucleus accumbens (collectively known as the striatum), globus pallidus
(internal (GPi) and external (GPe)), subthalamic nucleus (STN) and substantia nigra
comprise the basal ganglia. Excitatory and inhibitory signaling occurs between the nuclei
in the basal ganglia, as well as to other areas of the brain (Figure 1). Dopamine - a key
neurotransmitter involved in facilitating signal pathways - is produced by dopaminergic
cells of the substantia nigra.

Figure 1 – Signaling pathways connecting the basal ganglia (yellow box) and
surrounding cortical and thalamic areas. In the “Parkinsonism” diagram, thin lines
represent a decrease in signaling, thick lines represent an increase in signaling. Blue
represents inhibitory signaling, red represents excitatory signaling. SNc, substantia nigra
compacta; SNr, substantia nigra reticular; GPe, globus pallidus external; GPi, globus
pallidus internal; CM/PF,VA/VL, thalamus; STN, subthalamic nucleus; PPN,
pedunculopontine nucleus; SC, superior colliculus; LH, lateral habenula [33].
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The substantia nigra, located in the rostral midbrain, is comprised of two parts,
compacta and reticular. The dopaminergic cells of interest are located in the substantia
nigra compacta (SNc) which projects to the striatum. A simplified signaling pathway
from the SNc to the motor cortex begins with dopamine produced in the SNc traveling to
the striatum. From the striatum, inhibitory signals relay from the putamen to the GPe,
inhibition from the GPe to the STN, excitation from the STN to the GPi, inhibition from
the GPi to the thalamus, and excitation from the thalamus to the motor cortex. This
activation modulates motor and cognitive functions. This entire process functions as a
loop, with an signal originating in the cerebral cortex, modulated by the basal ganglia,
and the appropriate commands sent back to the cortex for action initiation [34].
The destruction of dopaminergic cells that occurs with Parkinson’s disease
disturbs these pathways. The decrease in striatal dopamine leads to decreased inhibition
from the GPe to the STN, therefore increasing excitation from the STN to the GPi, which
leads to increased inhibition from the GPi to the thalamus, and decreased activation from
the thalamus to the cerebral cortex [34], [35]. The dopaminergic signaling from to the
striatum affects reward-seeking behavior and motor control functions [36], [37], which
are markedly effected with PD. The symptoms manifesting from dopamine loss are listed
above in Table 1.
In addition to altered signal magnitudes in the dopaminergic pathways, people
with PD also experience changes in signal firing patterns. Animal and human studies
have shown abnormal oscillations of frequency in the GPi and STN, as well as abnormal
synchronization of neighboring neurons [38]. Additionally, structural connectivity in the
cortical and subcortical regions and their projections to other brain regions of PD patients
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with cognitive impairment has shown to be significantly decreased compared to healthy
controls [39]. Although decreased dopaminergic signaling from cell death in the STN
defines PD and can explain most motor dysfunction, Lewy body aggregates present in
non-dopaminergic brain structures also contribute to PD symptoms. Areas involved with
acetylcholine signaling and production in particular (such as the pedunculopontine
nucleus and the nucleus basalis of Meynert), can be adversely affected by Lewy bodies
and are related to postural control and compensatory motor strategies in dynamic balance
control [40]. These different functional breakdowns illustrate the complexity of the
neurobiology of PD and the challenges faced in developing disease treatments.
1.1.2 Motor Symptoms
Parkinson’s disease symptoms vary greatly across individuals, and are often
characterized by two main subtypes: tremor dominant, and postural instability and gait
difficulty. As the name suggests, the severity of tremor symptoms is greater than postural
instability and gait severity in tremor dominant, and vice versa. These classifications are
general, and mixed symptomology is common as well [41]. These subtyped may also be
expressed at tremor or akinesia-dominant, and have similar categorical criteria to tremor
or postural instability and gait difficulty groupings [42].
1.1.2.1 Gait
Descriptions of Parkinson’s disease gait includes stooped posture and shuffling
gait [3], which is the culmination of slowness of speed, reduced arm swing, reduced
stride length and decreases in joint ranges of motion [14]. Although normal slowed gait
speed involves smaller, slower steps, hypokinesia, bradykinesia and rigidity are the
sources of gait declines in PD. Bradykinesia is the overall slowness of muscle
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movements, while hypokinesia limits step size, therefore decreasing stride length.
Rigidity increases muscle tone inappropriately, inhibiting the full speed and extension of
limbs [40].
Compared to healthy controls, PD specific gait declines, known as shuffle gait,
typically include decreased speed [11]–[19] and decreased step length [11], [12], [14]–
[19], yet no difference in cadence (steps per minute) [11], [13], [15], [16], [19]. These PD
gait characteristics demonstrate a slowed walking speed attributed to shorter step length
[12], [43], with increased double leg support time [12], [16], [17], [20] and increased
stance phase [16], [44] representing gait stabilizing tactics. The kinematics of lower
extremity joints often align with decreased step length and exhibit an overall decrease in
range of motion (ROM) of the hip, knee, and ankle joints [11], [14]–[17], and typically
inversely correlate with disease severity [11].
Biomechanical analysis of PD gait includes studies with participants both “on”
[18], [45], [46] and “off” [11], [17], [47] medication, and significant gait declines exist
for those with PD compared to healthy peers under both conditions. However, the type
and degree of severity of outcome measures in which changes are seen differs between
“on” and “off” medicated state. For example, “off” medication, subjects may exhibit
significant declines in joint ROM for most of the lower extremity joints [11], [16], [17],
while “on” medication they may show significant declines in the ankle joint only [46].
When the same cohort of subjects are tested both “on” and “off” Parkinsonian
medication, some studies have indicated that levodopa has shown to elicit improvements
in spatiotemporal, such as velocity and stride length, and kinematic outcome measures,
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such as joint ROM, [11], [19], [47], [48], while other studies have shown a lack of
levodopa induced change in temporal measures such as cadence [48].
Differing responses to levodopa as well as information from healthy adults and
animal model studies contribute to the understanding of the underlying mechanisms of
Parkinsonian gait disturbances. Healthy gait function involves a combination of cognitive
and automatic processes to initiate, continue, and augment gait and posture. The
cerebellum regulates and integrates feed-forward cognitive processes from the cerebral
cortex and sensory feedback processes from the spinocerebellar tract. The continual basic
gait pattern is engendered by central pattern generators, which are a spinal neural network
influenced by sensory feedback. The basal ganglia can also contribute to modulating gait
processes, with the midbrain dopaminergic neurons influencing this effect [49]. In PD,
loss of dopaminergic cells, reduced connectivity in areas responsible for motor
automaticity and reduced activation in cortical areas contribute to gait declines.
Dopaminergic cell loss can lead to bradykinesia and rigidity, and impaired automatic
motor functions necessitate compensatory neural recruitment, yet decreased neural
activity in cortical regions limits ones ability to effectively compensate with these areas
of the brain [42], [50]. Additionally, gait function has shown to predict cognitive decline,
highlighting the dependency of gait function compensation on cognitive function in PD
[51].
1.1.2.2 Arm Swing
Arm swing during gait is the pendulum motion of the arm traveling
anteriorly/posteriorly in the sagittal plane. Patients with Parkinson’s disease often show a
decrease in arm swing function compared to healthy peers, with decreased ROM for both
8

the elbow and shoulder joints [15], [52] decreased acceleration and increased asymmetry
between the right and left arms [52]–[54]. Decreases in arm swing excursion are to be
expected with decreases in velocity. However, characteristics observed in PD suggest
changes at a centrally mediated, subcortical level, independent of gait speed. Patients
with Parkinson’s disease who demonstrate decreased or loss of arm swing typically
experience these declines before lower extremity declines [55], and exhibit abnormally
timed muscle activations, both in a rhythmic pattern and randomly [56]. Parkinson’s gait
also experiences “phase shifting,” where the phases of the repetitive swinging motion of
the arms and the legs are not aligned as with healthy controls [57], [58]. In instances
where patients have an affected and unaffected side, the affected side (greater symptom
presentation) typically shows lesser arm swing motion, while the unaffected side might
not reach a significant difference compared to healthy controls [54], [59]. Furthermore,
dopaminergic modulation has shown the ability to alter impaired arm swing by
decreasing arm-to-arm swing asymmetry and increasing velocity in the affected arm [47],
[59], and subthalamic nucleus stimulation has shown the ability to decrease phase shift
and increase ROM [58].
1.1.2.3 Balance
Postural stability is a key aspect of mobility and ambulation, and applies to static
(such as stationary standing) and dynamic (such as walking, turning or responding to an
external force) conditions. With PD, both static and dynamic balance is affected.
Corrective muscular responses necessary to maintain an upright position under stationary
or destabilizing conditions can become inaccurate in PD, resulting in declines in postural
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stability and balance recovery [7], [60]–[62]. Poorly timed muscle activation driving
bilateral coordination employed during walking, can also lead to instability [20], [63].
Balance is a combination of vestibular, visual and somatosensory inputs and
regulation. The integration of modalities contributing to postural stability is impaired in
PD, leading to instability [64]. Decreased connectivity networks in pathways to the
occipital cortex [39] may impact visual processing, while disruption to the nigro-striatocollicular tracts in PD are believed to cause vestibular disturbances [65], potentially
contributing to postural instabilities [66]. Somatosensory input remains intact [67],
however, abnormal processing leads to inadequate recognition of the placement and
forces required for proper movement [64], and inappropriate scaling of response
movements under dynamic balance challenges [64], [67]. Neural synapses outside of the
basal ganglia and its direct projections are also impacted by PD. Acetylcholinergic areas
of the brain are adversely affected by Lewy bodies in PD, and may affect reactive balance
control [40]. Decreased muscle force production and disproportionally smaller reactions
may be attributed to bradykinesia, while rigidity contributes to increased background
muscle tone, inhibiting quick, reactive muscle movements [68]. The consequences of
poor postural stability often lead to falls and injury.
1.1.2.4 Fall Risk
As falls are common among older adults, they are more common amongst those
with Parkinson’s disease due to overall motor impairments. Recent studies report that on
average, 60.5% of people with PD report at least one fall, and 39% on average report
recurring falls [69]. The risk for falls increases with inadequate reactive postural
responses, gait declines and increased difficulties in DT conditions [70]. Recurring falls
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are common to about 50% of those who have previously sustained one fall [71]. Falls for
older adults pose a greater risk than a younger population, often resulting in serious
injuries such as hip fractures, which are accompanied by costly hospital and rehabilitation
visits [72]. In addition to physical and financial consequences, past falls may invoke a
fear of future falls, and is a strong predictor of future falls in PD [73]. This fear of falling
may potentially facilitate negative life changes, such as isolation and reduced physical
activity [74]. Furthermore, a reduction in physical activity can lead to poorer health
outcomes, and isolation can lead to decreased mental well-being [75].
The relationship between falls and physical activity in Parkinson’s disease is
complex. An inverted U-shaped relationship between falls and disease severity is
commonly seen in PD. At early disease onset with mild PD, falls tend to be infrequent; as
the disease progresses to the moderate severity, falls increase; and towards the greatest
disease severity falls return to infrequent. Ambulatory activity declines with age and
disease severity, and has its own intricate relationship with fall risk [76], [77].
Characteristics of ambulation and motor function which decline in PD can be
linked to increased fall risk, such as turning ability [78], retropulsion (loss of balance in
the backward direction) [73], freezing of gait (inability to initiate walking, the feet seem
“frozen” in place) [79], and poor balance recovery responses [7], [80]. Bradykinesia and
rigidity pervasively alter motor tasks, and contribute to motor declines which increase fall
risk [7], [68].
In addition to motor declines and their effects on fall risk, cognitive declines also
show association with falls in PD. Increased incidence of falls has shown to correlate
with increased cognitive decline [78], [81], and decreased brain volume in areas
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associated with attention [81]. Falls and fall risk in people with PD remains complex and
commands continued research in fall prevention.
1.1.3 Non-Motor Symptoms
In addition to motor function decline, people with PD experience a myriad of nonmotor symptoms, specifically cognitive function decline. The basal ganglia-thalamocortical circuits responsible for motor function have parallel circuits responsible for
associative/cognitive functions, which are also effected by impaired signaling in PD [33].
Executive function is mainly housed in the prefrontal cortex, and deficits in this area
become apparent through cognitive decline [34]. Decreased dopamine in the striatum and
its impaired connections to specific regions of the prefrontal cortex impact many of the
executive functions that decline with PD [82]. The basal ganglia and prefrontal cortex in
particular, play a role in allowing decidedly relevant information to be stored into
working memory [83]. Decreased activity in the striatal and prefrontal regions leads to
inappropriate signaling in the frontostriatal loop, resulting in declines in tasks measuring
working memory, set-shifting, planning, attention and cognitive flexibility [82].
Executive function declines in PD are detectible in various neuropsychological
tests [84]. For example, the N-Back test assesses working memory [85], serial-7
subtraction assesses attention and concentration, and the verbal fluency test assesses
semantic memory [86]. These different cognitive functions are interwoven into daily
tasks, and declines can significantly impair quality of life.
1.1.4 Current Treatment Methods
The conventional treatment methods for managing Parkinson’s symptoms that
directly target the brain include dopaminergic medication and deep brain stimulation.
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Delivering dopamine to the brain is complicated by the fact that dopamine cannot cross
the blood brain barrier; therefore, the precursor levodopa is administered orally. To
inhibit conversion of levodopa peripherally, prior to delivery to the central nervous
system, carbidopa or benserazide is combined with levodopa. This combination increases
the bioavailability of levodopa (and ultimately, dopamine) to the brain, and decreases the
side effects (nausea, vomiting) of increased peripheral dopamine [87], [88]. Overall,
levodopa medications improve motor and non-motor symptoms [47], [87], [89],
including gait function [47]. Although medications do improve symptoms, they do not
eliminate them completely. Gait parameters do not necessarily reach the values of healthy
controls, even during the peak of a dose cycle [19], [47]. Other drugs, such as
bromocriptine, pramipexole and ropinirole mimic the actions of dopamine in the brain to
provide similar affects [47].
In healthy individuals, dopaminergic neurons in the striatum metabolize, release
and reuptake levodopa. With decreased dopaminergic neurons in PD, serotonergic
neurons are recruited to convert and release levodopa. However, serotonergic neurons
lack dopamine receptors and appropriate feedback, therefore leading to poorly timed
dopamine release into the striatum contributing to motor side effects, such as dyskinesia
(involuntary movements) [87]. Additionally, the risk for developing dyskinesia increases
with earlier onset of the disease, as well as with higher cumulative levodopa medication
doses [90].
Deep brain stimulation is another effective treatment for PD, involving an
implanted device providing electrical stimulation to the brain [91]. Different target
locations are used, with each location of the electrodes targeting slightly different
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outcomes. Subthalamic nucleus stimulation primarily improves motor function and can
reduce the need for medication, GPi stimulation show improvements in mood and
cognition [91], the thalamic ventrointermedial nucleus is targeted for decreasing tremor
[92], and stimulation in the pedunculopontine nucleus region (PPN) targets decreases gait
freezing and postural instability [93]. Although some reviews have identified these
locations with targeted symptomatic relief, there is certainly overlap due to neural
connections and projections, such as tremor treated by both STN and GPi stimulation,
and improvements in gait function with STN and PPN. The most ideal stimulation sites
for maximum symptom relief are still being investigated, with increasing emphasis on
non-motor symptom relief [94]. Although some research has shown improvements in
cognition, sleep and attention with PPN stimulation [94], other studies have shown that
STN and GPi stimulation can result in declines in attention, memory and executive
functions [91] and further research is needed in this area.
Medication and deep brain stimulation are effective treatment methods for PD,
targeting brain function directly; however, the side effects of dyskinesia [3], [90], [95],
fluctuating effectiveness of the medications [96], and risks of surgery such as cost, device
malfunction [97], infection [24], [97] and decreased cognitive function [91] accompany
these treatments options..
1.2 Dynamic Balance - Perturbation Response
When an individual is destabilized by a sudden shift of balance, whether from an
impact to the body, or a tilt or shift of the floor beneath them, the body responds in efforts
to regain its balanced position. In addition to instinctual grasping reflex of the hands, the
muscles and joints of the trunk and lower body react to shift the body to best support
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itself. The muscular responses responsible for stabilization occur at different time points,
typically characterized as short latency (occurring first), medium, then long latency
(occurring last). It is believed that short latency responses are monosynaptic stretch
reflexes occurring in the spinal cord, and medium and long latency responses involve
muscle activations which induce balance recovery behaviors, such as grabbing for a
stabilizing bar, and function under cortical influence [98], [99]. These responses usually
involve flexion and extension of the ankle and hip joints to control anterior-posterior
displacements, and lateral trunk flexion and weight shifting between the legs to regain
control after lateral displacements [100]. One of two different strategies typically
dominates at the ankle or the hip, each involving contraction of the surrounding muscles
and motion at the joint [101]–[103], and is modifiable based on the most efficient option
for the surrounding conditions [98]. The EMG muscle response pattern to a platform shift
is typically a high EMG reading upon the initial movement, followed by tonic muscle
contraction while the body is in motion with the moving platform [7], [60]. Both young
and older healthy populations can appropriately scale their joint kinematics and kinetics
to the magnitude of an induced perturbation to regain their balance [104], meaning
muscle contractions and joint movements are directly correlated with the magnitude of
the perturbation intensity.
Balance reactions for a PD population deviate from the healthy, normal patterns
of balance recovery. Studies have shown differences in both muscle forces and activation
timing. When analyzing muscle EMG’s, the muscles of the lower limbs can be broken
into groups via their reflex activation times – short and long latency. In a backwards tilt
or shift for example, the tibialis anterior acts as the antagonist muscle, has a long latency
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response, and contributes to postural stability [99]. While short latency muscles exhibit
similar timing for PD and for controls, the tibialis anterior has a delayed onset [62],
[105]. Since the long latency response likely utilizes cortical control [98], [99], decreases
in postural stability in PD may reflect declines in cortical function. In situations with
varying degrees of tilt or shift intensity, PD patients exhibit difficulty scaling their
reactions appropriately. Studies have shown that PD patients do not exhibit significant
changes in measures such as rate of center of pressure (COP) excursion [106], joint
motion [104], and EMG response [62], [105] across varying perturbation intensities
[104], whether the level of intensity is known or unknown [62], [105], [106]. Often, the
active EMG response amplitudes are smaller than controls [7], [105], yet background and
passive EMG activity is larger [7], [60]. Center of mass displacement is also typically
greater than controls, while COP displacement is often smaller, indicating instability as
the closeness of these two measures is necessary for proper stability [61], [107].
Bradykinesia and rigidity may be responsible for the inability to scale responses properly
and inappropriate muscle activation [61], [68]. Dopaminergic medication alleviates
rigidity; however, this results in decreased muscle tone and a worsening in perturbation
response abilities [68].
1.3 Cognitive-Motor Dual-Task
Performing two simultaneous tasks requires a greater cognitive load than either
task performed alone. Cognitive-motor dual-tasks (DT) can be effective in understanding
task prioritization when mental resources are limited. Dual-task costs describe the effects
of a DT paradigm compared to each task performed individually as a single-task (ST).
Dual-task paradigms are sensitive enough to show both motor and cognitive dual-task
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costs in healthy young adults [108], yet versatile enough that they have been used
extensively with compromised populations.
Subjects with Parkinson’s disease generally exhibit greater dual-task costs than
healthy control subjects [109]–[112]. The manifestations of costs affecting gait include:
increased gait asymmetry, slower, shorter steps, increased double support time [113],
differences in gait profile, variability in torso and lower extremity joint rotations, [114],
and decreased arm swing [115].
In dual-task tests, individuals tend to prioritize one task over the other. The
“posture second” strategy – that individuals will allocate their attention primarily to the
cognitive task in a dual task scenario and experience declines in motor or posture – is
commonly observed in PD [20], [114], [116], [117]. However, other studies have shown
conflicting results where prioritization varies, often depending on secondary task type
[109], [118], [119].
Cognitive tests commonly utilized in dual-task paradigms include Stroop (both
auditory and visual), serial subtractions, spontaneous speech, text comprehension and
phoneme counting. Studies have shown variability in dual-task cost significance across
different cognitive tests. For example, comparing the auditory Stroop test and the
spontaneous speech test while walking in older adults, the spontaneous speech dual-task
resulted in greater effects on gait parameters [120]; and comparing a serial seven
subtraction test and the visual Stroop, the serial-7 subtraction test showed greater effects
on trunk measurements [121]. Comparing tasks with phoneme counting, text
comprehension and serial seven subtractions, only the serial subtractions test showed
significance in dual-task costs [109]. Although the purpose of these tasks under DT
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conditions is to provide excessive cognitive loading, they all address different aspects of
cognitive function which likely contributes to differing results.
The exact changes in signaling pathways in PD under DT conditions are
unknown; however, recent studies suggest activation extending beyond areas directly
related to the tasks at hand. These misdirected signals may illustrate the decreased
organization of neural signaling, impacting DT function [122], [123].
1.4 Technology
Detection of changes in motor function can be important in diseased populations
for identifying disease progression and monitoring the impacts of intervention [124]–
[126]. As technology has advanced, more objective measures have become available to
analyze gait parameters, increasing the detailed understanding of gait and balance and
how it is related to physical and neurological pathologies. Some of these technologies
include force plates, inertial sensors and motion capture [127]–[129]. Integrated
technology systems, such as the Motek Computer Assisted Rehabilitation Environment
(CAREN) system [130] combines technologies to maximize objective data collection.
1.4.1 Basic Principles of Motion Capture
Motion capture can be broken down into two essential parts: determining the
location of an object in space, and the changes in position of the object over time. The
first step, determining object location, involves motion capture cameras, the objects in the
space (often markers), and a series of equations. The process involves taking an object in
3-dimensional space, gathering information about its location in 2D space, and
reconstructing it onto a virtual 3D coordinate system. This is accomplished by using a
series of equations called projection equations. The point in space projects its image onto
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the camera lens creating a 2D image, accounting for the focal length, location, and
orientation of the camera relative to the space. Multiple cameras placed around the
motion capture space each collect a different image to discern the third dimension,
similarly to how stereopsis (binocular vision) of human eyes creates our perception of
depth [131]. Although it is possible to determine a marker location with two cameras,
three or more cameras are recommended for best results. To decrease the possibility of
marker occlusion, a greater number of cameras are used. With limited views of the
capture volume, markers can become out of sight (dropped), or incorrect markers can
appear where there is actually no marker (“ghost”). For example, if two markers lay in
the same horizontal plane, and their lines of sight to separate cameras cross, it may
appear that there is only one marker in the crosshair instead of two separate markers (see
Figure 2) [132]. Combining the information from the different camera views, a least
squares method equation can solve for the three unknowns: the x, y, and z positions of the
markers. These positions are calculated for every frame, and the changes in position over
time translate to motion.

Figure 2 – Example of possible “ghost marker” configuration
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When describing the location of objects in the capture volume space, two
coordinate systems are used: global and local. The global coordinate system can be
defined different ways, but it essentially describes the objects in the “original position”.
This may be defined in relation to the ground in the space volume, or as the marker
location in the first recorded frame. The local coordinate system is defined as the new
marker position after a rotation and/or translation in space, in relation to the new position.
Detecting motion relies on a mathematical relationship between the global and local
coordinate systems, see Figure 3.

Figure 3 – Calculating the relationship between two joint segments. This involves
comparing the relationship between the global-to-local transformation matrices of each
segment.
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With a motion capture system such as Vicon, the marker coordinates in the x, y,
and z planes are provided per timestamp (the number of timestamps per second depends
upon sampling frequency). Using this data, transformation matrices are created,
containing the rotation and translation information of each object in 3-dimensional space
from one timestamp to the next. To calculate relationships between body segments such
as joint angles, the transformation matrix relating the local coordinate system of the first
segment to the global coordinate system is created. Next, the transformation matrix
relating the local coordinate system of the second segment to the global coordinate
system in created. Finally, an equation describes the relationship between the two localto-global transformation matrices of each frame (see figure 5) [133]. Motion capture for
the human body often uses the coordinate system of the pelvis as the global coordinate
system, and the coordinate system of the segment of interest as the local coordinate
system [134].
To compute the angles between two objects such as the upper and lower arm
segments, the rotation matrix (part of the transformation matrix) is decomposed into x, y,
and z rotations, and the angles are extracted individually from matrix equations [135].
The order in which these rotation matrices’ calculations are applied is significant. When
measuring anatomical joints, this “joint angle sequence” will vary depending on which
joint is being measured, following the individual joint rotation pattern of
flexion/extension first, medial/lateral second, and interior/exterior rotation last [134].
1.4.2 Instrumentation (CAREN system)
Study assessment and data collection took place on the Motek CAREN system.
Located on the Cleveland Clinic’s main campus, CAREN is an integrative motion
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capture system, consisting of a Vicon 10-camera real-time motion capture system, a
Moog motion base platform with six degrees of freedom, a dual-belt treadmill with two
Forcelink force plates (one located underneath each belt), a 180-degree cylindrical
projection screen system, surround sound, and D-Flow software (see Figure 4).

Figure 4 – The Computer Assisted Rehabilitation Environment (CAREN) system at the
Cleveland Clinic, Cleveland Ohio.

Various data are collected from the system and are sent to D-Flow for processing.
These inputs are processed within module-based applications and allows for real-time
feedback. D-Flow provides a library of modules, each possessing unique qualities and
functions. Data streams into these modules and different connections between modules
process the data for output functions, calculations, changes to the system, etc (see Figure
5).
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Figure 5 – The flow of information through the CAREN system. The marker data from
the cameras is processed through Vicon and sent to the giganet computer to combine with
force data from the force plates. This information is processed in D-flow according to
programmed specifications. The outputs from the D-flow application can program
platform movement, treadmill speeds, and images on the screen.

The motion capture aspect of the CAREN system includes a passive marker
system and force plates. The motion capture system includes Vicon MX-T cameras,
which consist of a digital video camera, a strobe head unit, a lens, and optic filter. The
strobe unit consists of LED’s (Light Emitting Diodes) that shine infrared light on the
retroreflective spherical markers, which then reflect the light beam back to the cameras.
The force plates have six load cell sensors per plate - three in the Y direction (vertical),
two in the X direction (horizontal left-right), and one in the Z direction (horizontal
forward-backward). Two video cameras are also located on the rear-left and right of the
treadmill to capture live video. The video does not affect the data flow of the system, and
therefore was not included in the diagram (Figure 5).
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1.5 Exercise and Parkinson’s Disease
Exercise results in various positive effects on people with Parkinson’s disease,
including improvements in motor and non-motor functions [136]–[139]. Changes in
functions not directly related to the exercise task are of particular interest, as they suggest
centrally mediated changes at the cortical and subcortical areas of the brain. In gaining
understanding of the effects of exercise on the brain, animal studies provide valuable
insight, and have set a foundation for this area of research.
1.5.1 Animal Models
To induce Parkinson’s-like physiology in mice for animal models, 6hydroxydopamine (6-OHDA) is commonly injected to facilitate nigrostriatal neuronal
loss. Tillerson et al. discovered that increased use of limbs impaired by 6-OHDA
injection results in decreased loss of function as well as decreased loss of dopamine
located in striatal tissue [140]. Additionally, decreased used of the affected limb resulted
in the opposite: increased loss of function and increased loss of striatal dopamine [141].
These studies contributed to the foundation for investigating the neuroprotective role of
physical activity on PD. Subsequent animal studies have shown that high-intensity
exercise (typically treadmill running) in PD mice results in neuroprotective effects,
changes in neurotransmitter transport, and increases in neurotrophins [25]–[27], [142]–
[147]. The neuroprotective effects include increased defense from oxidative stress and
support of angiogenesis and synaptogenesis [25]. In addition to symptom improvement,
exercise in PD mice results in increases in dopamine D2 receptor mRNA, and significant
decreases in dopamine transporter [26], [27], decreasing dopamine reuptake into
presynaptic vesicles. With increased dopamine receptors and increased postsynaptic
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dopamine signaling, dopaminergic effects increase despite no differences in striatal
dopamine levels in PD + exercise mice compared to PD control mice [142]. These results
suggest that high-intensity exercise causes compensatory changes in the brain concerning
dopamine processing. Studies have also found increases in neurotrophins such as brainderived neurotrophic factor (BDNF), glial cell-derived neurotrophic factor (GDNF) and
insulin-like growth factors as a result of exercise [25], [143]. Furthermore, Gomez-Pinilla
et al. demonstrated a positive correlation between BDNF and proteins involved in cellular
metabolic processes [147]. The proteins include: AMPK which monitors energy levels in
cellular metabolism [145], uMtCK which is involved with energy maintenance and
transduction [144], and UCP-2 which regulates energy metabolism by uncoupling
mitochondrial electron transport during ATP synthesis [146].
1.5.2 Human Exercise Research
Methods of neuropathological data collection used in animal model studies are
often invasive and result in subject sacrifice; therefore, alternative testing methods are
employed for human studies investigating neurophysiological effects of exercise.
Peripheral neurotrophic factors have been shown to increase from exercise interventions;
however, this is not an exact measure of the neurotrophic factors in the brain [148]. Other
methods to study brain activity, such as non-invasive fMRI tests have been used in
human studies with cycling interventions [28], [149]. Physical outcome measures
representing symptom improvement are also used to assess changes in a PD population
due to an exercise intervention, such as the UPDRS assessment or accelerometers
measuring tremor. Exercise programs with mixed tasks (such as cardiovascular, strength,
balance, stretching, etc.) have shown improvements in motor function measured by the
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UPDRS, improvements in walking [136], [137], and balance ability [136]. Forced
exercise cycling studies have shown improvements post-intervention in UPDRS scores
[29], [30], [149], tremor [150], manual dexterity and force [28], [30], and shoulder ROM
[151]. Improvements in upper extremity function (a part of the body not actively involved
in the exercise) and changes in brain activation following forced exercise resulting in
excitation in the basal ganglia (specifically the putamen, globus pallidus, thalamus,
subthalamic nucleus) [28], [149], and the cortical and subcortical areas [28] suggest
centrally mediated changes. Improvements in overall motor function can have profound
effects on daily activities.
The effect of exercise interventions on motor function as it applies to dynamic
postural control is particularly important in PD as improvements in balance can lead to a
decreased risk of falls [152]. Most studies using an exercise intervention assessing
postural stability show significant improvements in balance measures from balance
training when the training targets the specific movements tested in the outcome measures
[153], [154]. Additionally, task-specific balance training improvements have shown to
sustain up to six months post intervention [155]. Although it is encouraging that people
with PD can improve dynamic postural stability with interventional training, these results
demonstrate that motor skill learning abilities are still present in people with PD [152].
Less is known about the effects of exercise on centrally mediated changes in balance in
PD. A few studies show improvements in postural stability with training not specifically
targeting outcome measures, such as weighted treadmill walking, with improvements in
the Berg Balance Scale [156] and improvements in the pull test portion of the UPDRS
[157], while cycling training has shown improvements on the Berg Balance Scale [158].
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Improvements in balance measures resulting from cardiovascular exercise are promising;
however, more objective outcome measures will strengthen the knowledge of how
exercise impacts dynamic postural control.
Exercise interventions investigating changes in gait parameters range from
treadmill training [158], [159], to dancing [160], [161]. Overall, most exercise
interventions elicit some improvements in gait [160], [162]. Similar to balance training
targeting improvements in postural stability measures, many interventions targeting
improvements in gait measures are treadmill or walking based [162]–[164]. Other studies
focusing on strength training experienced improvements in gait parameters [165], [166],
which may be due to improvements in muscular function [167], [168]. High-intensity
cycling training has shown improvements in gait measured by the Timed Up and Go test
and increased gait speed [158], and although common gait measures have objective
quantifiable results, such as time, distance, etc., tests like the Timed Up and Go test and
6-minute walk test fail to describe quality of gait. A study by Mirek et al. used motion
capture technology to characterize changes in gait in greater detail, such as joint ROM,
due to exercise intervention [169]. Understanding methods to improve PD gait is crucial
for decreasing fall risk; however, walking while mentally occupied further decreases gait
function and poses a greater risk. Although there is a growing understanding of how
exercise can improve gait in PD, there is little known of how exercise can affect gait
under DT conditions.
People with PD experience increased gait deficits when performed simultaneously
with a cognitive task [109]–[112], and efforts are being made to uncover interventions to
improve DT abilities in PD [170]–[172]. Improvements in DT performance are often
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elicited through DT training [173]; however, less is known on how interventions
dissimilar from DT training affect gait under DT conditions. A study by Altmann et al.
investigated how aerobic cycling exercise affects DT performance; however the motor
portion of the DT test was cycling as well [171].
In addition to effects on physical outcomes, exercise can also result in positive
effects on cognitive function. A meta-analysis by Colcombe and Kramer concluded that
aerobic exercise increases cognitive test performance across different cognitive tests,
exercise programs, and participant characteristics. Of these results, executive control
processes demonstrated the greatest improvements [174]. Additionally, studies have
shown increases in brain mass in the prefrontal, temporal, and cortical regions as a
response to aerobic exercise [175]. Following this trend, exercise interventions with a PD
population involving moderate- to high-intensity aerobic exercise also exhibit cognitive
improvements. Similar to Colcombe’s findings, the greatest improvements occurred in
executive function tasks [139], [176], [177].
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CHAPTER II
SPECIFIC AIMS, STUDY DESIGN AND PARTICIPANTS
2.1 Specific Aims
Aim 1: To determine the effects of an intensive aerobic cycling intervention on
postural responses following an induced platform perturbation. This assessment was
an application developed by Motek as part of a battery of assessments for patients with
Parkinson’s disease. The “Time to Stability” application quantifies postural responses by
measuring time and body mass excursion. The test begins with the participant standing in
the center of the force plate with both feet firmly planted in a comfortable, narrow stance.
The center of pressure is recorded by the system and stored. A series of platform shifts
occur in four directions, at varying time intervals, and different accelerations. The
direction and time interval are randomly programmed, and the acceleration remains
constant for each test (three tests will be performed, one at each acceleration). Before
each shift, the platform returns to center and a visual cue lets the participant know that
the next platform shift is approaching.
Subjects completed this assessment once before beginning the exercise regimen to
establish their “baseline” values, and once after completion. Baseline scores were
compared to the post-exercise scores of each individual participant.
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Aim 2: To determine the effect of an intensive aerobic cycling exercise on
biomechanical gait parameters and cognition in ST and DT conditions. Three tasks
were performed to evaluate ST and DT changes: a self-paced walking ST, three cognitive
ST’s, and three walking/cognitive DT’s. Biomechanical gait parameters were quantified
as walking speed, cadence, step length, joint angles, marker movement, and gait
regularity. The verbal fluency test, the serial subtractions test, and the N-back test served
to assess executive function, attention and working memory in the single tasks, as well as
to increase cognitive loading in the DT conditions. All tests proceeded for 60 seconds.
Subjects completed the gait assessments once before beginning the exercise
regimen to establish their baseline values, and once at the end of the intervention.
Comparisons were made between baseline and post-exercise for ST and DT conditions to
assess changes due to the exercise intervention, as well as between ST and DT conditions
to assess changes due to DT cognitive loading.
2.2 Subjects
Forty-five participants were recruited for this study, comprising three subject
groups: PD intervention (PDE), PD non-intervention control (PDC), and healthy agematched control (HC). Forty-two subjects participated, 14 per group; one participant in
the PDE dropped out due to physical inability to complete study tasks, one participant in
the PDC group dropped out due to a broken shoulder, and one age-matched participant in
the HC group was removed to equalize the groups. Participants were recruited from the
CYCLE clinical trial (R01NS673717) in the Neural Motor Lab [178], and those who
participated in past studies and indicated willingness to be contacted in the future. The
intervention group included exercisers in both the forced and voluntary cycling groups,
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and the PD non-intervention group included some individuals who have already
completed the CYCLE Trial. Recruitment involved asking participants: if they were
willing to be contacted about a concurrent additional study, a phone call follow-up
involving educating the participant about this study, review of the consent form, and the
researcher answering any and all questions. Age-matched healthy control subjects were
recruited from the subjects with Parkinson’s. The Parkinson’s subjects (both intervention
and non-intervention groups) were asked if they have a spouse, friend, family member,
etc. in the same age range who may be interested in participating. The inclusion criteria
for the healthy control participants are that they are within three years of age of the
subject with whom they are matching, and must be able to stand unassisted. The
exclusion criteria include: known neurological or balance disorders. The primary
inclusion criteria included: clinical diagnosis of idiopathic Parkinson’s disease; between
ages 30-75 Hoehn and Yahr stage II-III when on antiparkinsonian medication; not
currently involved in formal exercise intervention or clinical study; ability to stand
unassisted. The primary exclusion criteria included: existing cardiopulmonary disease or
stroke; dementia; and any medical or musculoskeletal contraindications. The subject
consort diagram is illustrated below (Figure 6), as well as baseline demographics (Table
2) and a sample of outcome measures from the exercise intervention for the PDE group
(Table 3).
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Baseline
Testing

PDE

PDC

HC

PD exercise
intervention*
N = 15

PD control (no
intervention)
N = 15

Healthy Older
Adults
N = 15

EOT
Testing

PD exercise
intervention
N = 14

Final
Analysis

PD exercise
intervention
N = 14

One drop
out due to
disease
severity
and
physical
discomfort

One drop
out due to
broken
shoulder

PD control (no
intervention)
N = 14

PD control (no
intervention)
N = 14

One agematched
subject
removed to
equalize
groups
Healthy Older
Adults
N = 14

Figure 6 – Subject consort diagram. PD, Parkinson’s disease; EOT, end of treatment.

Table II – Subject baseline demographics
Mean (SD)

PDE

PDC

HC

Number of subjects

14

14

14

Gender (male)

8

9

4

Age (yrs)

64.9 (5.4)

62.2 (7.1)

64.0 (5.0)

Leg Length (m)

0.83 (0.06)

0.83 (0.04)

0.80 (0.04)

Weight (kg)

76.80 (20.89)

88.46 (20.01)

74.17 (15.04)

Hoehn and Yahr

2.2 (0.4)

2.2 (0.4)

stage

PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease control group; HC,
healthy control group.
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Table III – Exercise intervention mean outcomes of PDE group
Outcome variable
# of sessions attended
Heart rate during session (beats/min)
HHR during exercise sessions (%)
Cadence (revolutions per minute)

Mean (SD)
23.71 (0.82)
115.10 (14.63)
69.50 (11.79)
75.97 (13.01)

HHR, % heart rate reserve.

Participants were off antiparkinsonian medication for this study. In addition to
physical improvements due to medication, dyskinesia caused by levadopa has shown to
result in decreased postural stability, exaggerated arm swing, and increased sway during
stance phase [47]. Eliminating factors that alter the subjects physically increases the
integrity of the measurements.
2.3 Study Design
Data collection for both Aim 1 and Aim 2 occurred during the same testing session. The
order of data collection is illustrated below. Testing proceeded from top to bottom, tests
aligned horizontally occurred in random order (see Figure 7)
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Pre/Post-Intervention
Time to Stability (Aim 1)

0.25 m/s

2

0.50 m/s

2

1.00 m/s

2

Walking-Cognitive Dual-Task (Aim 2)
Single Task

Serial-7 Subtraction
Single

Verbal Fluency
Single

N-Back
Single

Walking
Single

Dual Task

Serial-7 Subtraction
Dual

Verbal Fluency
Dual

N-Back
Dual

Figure 7 – Order of testing session. Tasks listed vertically are in chronological order
(beginning at top), tasks listed horizontally are randomized.

The CYCLE trial intervention duration was eight weeks, with three exercise
sessions per week (totally 24 exercise sessions). Participants completed a cardiovascular
stress test prior to the start of their intervention to determine maximum heart rate reserve.
Exercise sessions included a five-minute warm up, a 40-minute high-intensity exercise
session, and a five-minute cool down. Subjects in the PDE group were comprised of
exercisers in both the voluntary (self-paced cadence) and forced (bike-set cadence)
exercise groups from the CYCLE trial. Despite differences in group assignment, all
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exercisers were either programmed or encouraged to exercise at resistance and cadence to
keep their heart rate in 60-80% of their heart rate reserve [178].
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CHAPTER III
DYNAMIC BALANCE RECOVERY
3.1 Introduction
Postural instability is one of the cardinal motor symptoms of PD [10]. Poor
balance can increase fall risk, decrease balance confidence and lead to decreased physical
activity [74]. Dynamic stability, particularly motor responses to perturbations, can be
important in navigating daily balance challenges. Specifically, medium and long latency
muscle responses, which participate in feedback loops associated with the cerebellum and
basal ganglia [179], are impaired with PD, and take longer to initiate and process under
balance destabilizations [62].
Physical training interventions aimed at improving postural stability in older
adults can improve reactive recovery responses and reduce incidence of falls [180].
Various types of exercise and physical training have also proven beneficial in those with
mild to moderate PD [136], [181]. Animal models have demonstrated changes in
neurotropic factors post exercise along with PD symptom improvement [26], [27], [142],
while human studies have shown improvements in UPDRS scores as a result of highintensity cycling [29], [30], [149]. The findings that dopaminergic therapy does not
improve postural control [47] suggest that non-dopaminergic regions of the brain impact
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dynamic postural stability [40] and support the exploration of treatments alternative to
medication. This study aims to investigate if a high-intensity cycling intervention can
elicit centrally mediated changes in the areas that affect improvements in dynamic
balance.
Healthy individuals possess the ability to central-set, or prepare sensory and
motor systems to react appropriately to an anticipated change in physical surroundings,
such as a platform perturbation. This, in turn, can decrease the time spent in regaining
balance [182]. This central-set ability is decreased in PD, and patients often lack the
ability to appropriately scale their muscular responses to changing stimulation [68],
[182]. This study aims to investigate how individuals with PD differ from healthy peers
in their ability to scale motor responses, how quickly and accurately the responses are at
regaining balance, and if exercise can improve these balance measures in people with PD.
The time taken to regain balance and the center of pressure excursion represent the
resultant physical movements of compensatory postural adjustments necessary to regain
postural stability after a balance destabilization.
3.2 Methods
3.2.1 Testing Procedure
The “Time to Stability” application, developed by Motek Medical, functions by
destabilizing the subject, and measuring their postural response performance.
Destabilization occurs via unexpected, horizontal displacement of the platform. The test
measures the time taken to regain balance after destabilization, and center of mass
displacement.
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Prior to test initiation, the system calibrated the subject by estimating center of
pressure (COP). Once successfully calibrated, the platform underwent a series of shifts,
inducing a temporary loss of balance. After the subject reestablished postural stability
and returned to their original, balanced position, the platform slowly returned to the
center, neutral position and prepared for the next shift.
Studies have demonstrated significant impairments with perturbation response
scaling in Parkinson’s disease [62], [102], [183]. To assess differences among various
difficulty levels, a total of three tests were performed (in random order), one at each
acceleration level: 0.25 m/s2, 0.5 m/s2, and 1.0 m/s2. At each level, eight shifts occurred,
two in each direction: forward, backward, left and right. The platform displacement was
the same for all shifts, at 0.081 meters. Upon the start of each shift, an orange circle
appeared on the screen, warning the subject of the impending platform shift. After the
appearance of the orange circle, the platform shifted after a random time delay between
one and four seconds. The unknown direction and timing of the shifts intended to reduce
anticipatory postural adjustments. The subject’s feet were separated by 5.0 cm to
standardize the base of support between trials. A narrow base was chosen based on
previous findings that a narrow stance results in a significant difference in center of mass
displacement between people with Parkinson’s and controls, where no significant
difference was seen in a wider stance [61].
Friedman’s ANOVA’s revealed no significant difference between shift directions
within an acceleration level for any subject groups (p > 0.05), therefore all eight shifts
were collapsed per acceleration level.

38

3.2.2 Instrumentation
The Time to Stability application utilized various components of the CAREN
system to provide testing conditions and for data collection. The forces exerted through
the feet, measured from the force plate are used to estimate the center of pressure (COP).
The platform, controlled by hydraulic motors, induced the perturbation shifts. Images
projected on the surround screen provided a visual testing environment, and minimal
visual cues. The D-Flow software orchestrated the functionality of the test, as well as
collected and completed preliminary processing of the data.
3.3 Data Analysis
The “Time to Stable” (TTS) outcome is the time in seconds from when the
platform has reached its maximum displacement to when the estimated COP has reached
“balanced”. During calibration, the average COP and standard deviation of the average
COP is calculated. The subject is considered balanced when the standard deviation of the
COP (measured in both the medial-lateral and anterior-posterior directions for 100 ms) is
lower than the initially recorded measurement. The COP outcome measure is provided by
the application in both the anterior/posterior and left/right directions as a coordinate
value. The COP excursion (COPex) outcome measure is obtained from the COP data
along both the anterior/posterior and left/right axes, and is collected over the same time
frame as the TTS measure. Both TTS and COPex are reported as the average of the eight
shifts performed within the same acceleration magnitude.
The COPex is the 2-dimensional path of the COP during a perturbation shift,
calculated using the ‘arclength’ Matlab function [184]. Prior to computing the path length
of the 2-dimensional COP, noisy data was processed using a threshold and interpolation
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method. The D-Flow software calculates the COP from each force plate individually, (left
and right) and takes the weighted average of the two. Instances where one foot lifts off of
the platform are not properly accounted for, and the lack of consistent contact force
between the two standing feet could lead to mathematical calculations resulting in
distances outside of the reasonable limits of stability. This process involves removing
noise point by point based on the theoretical speed that the point is traveling. Based on
previous studies measuring speed of COP [185]–[187], a maximum threshold of COP
speed was set at 0.50 m/s. First, the 2-dimensional speed of each COP point is calculated
by two data points in chronological order from the first point to the end of the trial. Upon
each comparison, the second time point of a pair is removed if the speed is above the
threshold, and replaced with the coordinates of the previous point. This process handles
noise based on physical properties, while leaving the “true” COP data signal untouched.
On average, < 10% of the data was removed/replaced using this method.
Shapiro-Wilk normality testing revealed non-normally distributed data for over
50% of the TTS data; therefore, nonparametric measures were used for all TTS data
analysis. For baseline comparisons between groups, a Kruskal-Wallis ANOVA was
performed. A Friedman’s ANOVA was used to determine the difference between shift
levels (0.25 m/s, 0.5 m/s, 1.0 m/s) for baseline and, if applicable, EOT testing sessions of
all subject groups. If significant differences were found, Wilcoxon Signed Ranks tests
were used for pairwise comparison. Wilcoxon Signed Ranks tests were also used to
compare baseline to EOT of outcome measures. To test for differences due to the
exercise intervention, the ΔTTS was calculated (EOT – baseline) and compared between
the PDE and PDC groups for each acceleration level using Mann-Whitney U tests.
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The results of Shapiro-Wilk normality testing of the COPex data revealed normal
distribution; therefore, one-way, two-way, and two-way repeated measures ANVOA’s
were used for COPex analysis. Where significance was found, pairwise comparisons with
Bonferroni corrections were completed. For baseline comparisons between groups a twoway ANOVA comparing factors of group (PDE, PDC, HC) and acceleration level was
used. A two-way repeated measures ANOVA investigating the factors of session
(baseline and EOT) and acceleration level was completed for both PDE and PDC groups.
Due to unforeseen loss of data, COPex data analysis included the PDE group: N = 12, the
PDC group: N = 6, and the HC group: N = 7.
3.4 Results
3.4.1 Time Taken to Regain Balance
Comparing baseline measures between the PDE, PDC and HC groups, no
significant differences were found for time taken to regain balance for all three levels of
acceleration. Differences in TTS across the three acceleration levels were compared for
each group, as well as each testing session (baseline and EOT for PDE and PDC, baseline
only for HC). The PDE group at baseline showed significant differences between
accelerations: the median TTS during the 0.5 m/s acceleration was 50.7% longer than the
0.25 m/s acceleration (Z = -2.57, p < 0.05); and the median TTS during the 1.0 m/s
acceleration was 41.4% longer than the 0.25 m/s acceleration (Z = -2.76, p < 0.01); and at
EOT the 1.0 m/s median acceleration experienced a 26.0% longer TTS than the 0.25 m/s
acceleration (Z = -2.57, p < 0.05). The PDC group at baseline showed that the median
TTS at the 1.0 m/s acceleration was 40.5% longer than the 0.25 m/s acceleration level (Z
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= -2.39, p <0.05), and there were no significant differences between acceleration levels at
EOT. For the HC group, the 3 accelerations levels were not significantly different.
Significant differences in TTS comparing baseline to EOT testing sessions are
seen in the PDE group with the 0.5 m/s median acceleration decreasing by 22.1% (Z =
2.76, p < 0.01). The PDC group did not show any significant difference in TTS from
baseline to EOT for any acceleration level. In comparing the ΔTTS between the PDE and
PDC groups, no significant differences were found at any acceleration level (see Figure
8). Results listed in Appendix A.
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Figure 8 – Time to Stable median results in seconds for all three subject groups. PDE,
Parkinson’s disease exercise group; PDC, Parkinson’s disease control group; HC, healthy
control group; EOT, end of treatment. Square inside 25%-75% box indicates mean.
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3.4.2 Center of Pressure Excursion
At baseline, there was a significant main effect of group; the mean COPex for the
HC group was 16.6% larger than the PDC group (t = 2.86, p < 0.05). There was no effect
of level or interaction at baseline. The two-way repeated measures ANOVA for the PDE
group revealed a significant main effect for the testing session, F(1, 11) = 7.91, p < 0.05,
such that the average COPex during EOT testing decreased significantly from baseline
testing by 0.17 meters (SD = 0.05). The main effect of acceleration level was nonsignificant, nor was the interaction effect. The two-way repeated measures ANOVA for
the PDC group yielded no significant main effects for testing session, acceleration level,
or their interaction effect (see Figure 9). Results listed in Appendix B.
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Figure 9 – Center of Pressure Excursion mean results in meters, for each acceleration
level (m/s2). PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease control
group; EOT, end of treatment.

3.5 Discussion
Both PD groups did not differ from the HC group on time taken to regain balance
for any of the three acceleration levels. Contrary to previous studies [104], [188], there
was not a clear difference between the PD groups and the HC group in terms of ability to
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modify perturbation recovery time to different acceleration levels. The PDE and PDE
groups had significant differences in TTS in one or two levels at baseline, which differs
from the hypothesis that the PD groups would be less able to scale their recovery time
responses than the HC group, and would take similar amounts of time for all three
different accelerations. The results of this study did not demonstrate a lack of scaling of
postural responses in a PD population as anticipated; however, these results are similar to
other studies which have shown intact or partial gain scaling, but decreased amplitude
[104], [107]. Studies that have demonstrated significantly slower perturbation responses
and decreased ability to scale postural responses compared to controls had PD patient
populations with greater disease severity, suggesting that disease severity may contribute
to degree of dynamic stability deficits [61], [105]. Additionally, Schieppati and Nardone
have found that PD patients with mild impairment show similar muscle activation
patterns compared with age-matched healthy controls [62], and Dimitrova, Horak and
Nutt found that muscle coactivation in response to a perturbation significantly correlated
with disease severity (subjects ranging from 1-4 on Hoehn and Yahr scale) [60].
The time taken to regain a balanced position, measured here as TTS, represents
the time taken for motor responses to adequately stabilize the body. This process involves
muscle responses from both cortical and subcortical activation with variable activation
latencies, [60], [68], [98], [99], [182], and may not be well characterized by time alone.
The movement of the COP may provide additional information on how the body
responds to perturbations.
Although numerous balance deficits in PD are well established, center of pressure
excursion specifically has not been well studied in the PD population. The results of this
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study indicate no significant differences between the COPex of mild to moderately
impaired individuals with PD (for the PDE group) and healthy older adults, which
mirrors the findings of a similar study [189]. Although there was a significant difference
between the PDC group and HC at baseline, there was no significant difference between
the PDE and PDC groups. Therefore, further analysis proceeded as intended.
Comparing the results of the PDE and PDC groups of this study, the PDE group
shows a significant decrease in COPex, whereas the PDC group has no significant
change. Previous studies demonstrate that higher COP excursion indicates worse
functional balance [187], [190], [191], therefore suggesting improvement in the PDE
group. Although interventions employing physical activities which practice a balance
component have shown efficacy in improving postural stability in a PD population [180],
[181], anti-Parkinson’s medications have not shown consistent improvements in balance
deficits [47], [68]. Impaired acetylcholine signaling pathways related to postural control
can be damaged by Lewy body aggregation, adding to the complexity of PD balance
impairment, and perhaps explaining the lack of improvement from medication [40].
Furthermore, potential improvements in dynamic balance resulting from an exercise
intervention not only demonstrates the ability of people with PD to improve their balance
from a task that does not practice balance, but it also suggests that exercise may elicit
changes differently than the levodopa-replacing mechanism of medication.
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CHAPTER IV
GAIT AND DUAL-TASK
4.1 Introduction
In healthy individuals, neural coupling controls the cyclical movement of arm
swing and leg movements during walking gait, and is likely controlled by central pattern
generators [192]. The integration of spinal cord output and higher level executive
processes results in successful gait performance [192]. These neural circuits are disrupted
in PD [33], resulting in gait impairments such as stooped posture, decreased speed,
reduced arm swing, reduced stride length, decreases in joint ROM, [14], yet no difference
in cadence (steps per minute) [11], [13], [15], [16], [19]. Gait stabilizing tactics also
common to PD gait include increased double leg support time [12], [16], [17], [20] and
decreased swing phase [16], [44]. The magnitude of gait impairment is typically inversely
correlated with disease severity [11].
Gait deficits present in PD are further exacerbated under DT conditions.
Decreases in task performance occur when two tasks are performed simultaneously in a
healthy population; however, those with PD generally exhibit greater dual-task costs than
healthy peers [109]–[112]. Under DT conditions people with PD may experience the
following: increased gait asymmetry; slower; shorter steps; increased double support time
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[113], differences in gait profile and variability in pelvic tilt, pelvic obliquity, pelvic
rotation, hip flexion/extension, hip abduction/adduction, knee flexion/extension, and
ankle dorsi/planar flexion [114].
People with PD also experience non-motor symptoms, such as cognitive decline.
The basal ganglia-thalamo-cortical circuits that cause motor declines when affected by
PD have parallel associative/cognitive functions [33]. The impact of PD on executive
function results in declines that are detectible in neuropsychological tests such as logical
memory and associative learning [84]. Cognitive and motor declines are exacerbated
under DT conditions when attentional demands are increased and adequate neural
compensation is not available [119].
Disease modifying treatments are not yet available for PD, but dopaminergic
medication and deep brain stimulation provide symptom relief [3], [24]. Unfortunately,
side effects such as dyskinesia (involuntary movements) [3], and risks of invasive surgery
[24] are associated with these treatment options. High-intensity aerobic exercise targets
neurological modifications to alleviate symptoms as well; however, it is associated with
lower risk and potentially positive side effects.
Parkinson’s disease patients with relatively more severe gait declines show higher
prefrontal activation during gait tasks than PD patients with relatively milder gait
declines. This suggests compensatory neural activation to improve gait performance
[193]. Exercise studies have shown increases in volume in the prefrontal, temporal, and
cortex regions as a response to aerobic exercise, [175], suggesting that exercise may have
a direct effect on areas of the brain that affect gait function in PD. Studies investigating
cycling exercise and PD measured motor symptom outcomes [28]–[30], [150], and brain
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activation [28], with key findings related to motor function including 35% UPDRS
improvement at end of trial and improvements in upper extremity function (measured as
grasping forces and tremor). Exercising the lower extremity, while experiencing
improvements in symptoms of limbs not involved in the exercise suggest that the cycling
intervention facilitates neurophysiological changes directly impacting PD symptoms
[28]–[30], [150].
Exercise studies have also shown improvements in cognitive function, with the
greatest improvements in executive control processes [174]. These improvements have
also been found in PD with moderate to high-intensity aerobic exercise, and similar to
Colcombe and Kramer’s findings, the greatest improvements occurred in tasks involving
executive function [139], [176], [177].
Studies have shown significant improvement in gait function after an exercise
intervention [158], [159], [194]; however, individuals frequently encounter walking
conditions that are more complicated than the ST conditions commonly tested in clinical
environments. When an individual is walking while talking on the phone, answering a
question, recalling the directions to their desired location, etc., they are effectively
completing a cognitive-motor DT. Studies targeting DT performance improvement often
employ physical interventions based on DT movements and exercises [195]. Whether the
neurological effects of high-intensity exercise can affect DT performance in PD remains
unclear. In addition to lower extremity outcome measures illustrating changes in gait, it
has been suggested that arm swing may also serve as a proxy for gait function [115].
Research has shown that dopaminergic treatment has the ability to improve gait function,
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specifically arm swing [59]. However, it is unclear how a high-intensity exercise
intervention can improve gait function illustrated by arm swing.
This study aims to investigate the effect of a high-intensity cycling exercise
intervention with a PD population on gait parameters under ST and DT conditions. The
various biomechanical outcomes measured with a motion capture system will provide an
objective summary of changes in PD gait under different task conditions, and after
intervention.
4.2 Methods
4.2.1 Testing Procedure
Participants completed ST and DT testing on the platform in the CAREN
environment. The ST tests were completed first, with the participant seated on a chair
with the test prompts delivered visually on the screen. After all three cognitive ST tests
were complete, the participants walked on the treadmill for 60 seconds for the motor ST
test. Next, the DT tasks were performed, where the participant completed both the
cognitive and motor tasks simultaneously. The versions of the cognitive tasks were
different for each testing presentation to minimize learning effect.
Walking speed was self-selected by the participants using the self-paced feature
of the CAREN system. The “self-paced” speed algorithm uses the four anterior/posterior
iliac crest markers of the pelvis to adjust the treadmill speed to the pace of the individual
relative to their positon on the treadmill. Once the participants audibly declared their
speed “comfortable” and “constant”, that speed was recorded and manually entered for
all walking trials in that testing session. The speed was held constant for the ST and DT
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trials in the same session to minimize the confounding effect of speed on other gait
parameters that may change due to DT effects.
4.2.2 Instrumentation
The application used for providing testing conditions as well as collecting and
completing preliminary data processing was custom built in the D-Flow software. In
addition to the hardware of the CAREN system used to create the testing environment
and data collection, the HBM with its specific marker model and the Gait Offline
Analysis Tool were used for initial data processing.
4.2.2.1 Software - Human Body Model
The Human Body Model (HBM) developed by Motek Medical uses marker and
force plate data to estimate subjects’ kinematics. The model has 18 body segments and 46
degrees of freedom, with the pelvis serving as the root segment. Although complex, this
process computes with sufficient speed to function in real-time, while the subject is on
the system (Figure 10). The first step involves calibrating the model to the subject. The
initialization uses the marker coordinates, marker diameter, and knee and ankle width to
calculate joint centers, bone lengths and joint axes. The subject weight and gender are
used to calculate the mass properties of the model. Data extraction and body segment
compilation use reference frames, defined during the initialization pose, illustrated below
(Figure 11). Generally, the origin of each segment lies at the proximal joint, and the Z
axis is oriented to go through the distal joint, in accordance with de Leva [1].
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Figure 10 – Data processing through the Human Body Model (HBM) [1].

Formulas unique to each joint, and anatomical information available from
surrounding markers are used to calculate the joint centers. The coordinate system for
HBM is: X=anterior; Y=left; Z=up. The hip joint center, for example, uses an algorithm
presented by Bell at al. [196]:
- X of hip joint center is X of greater trochanter marker
- D is distance between LASIS and RASIS
- Y of right hip joint center is Y of RASIS + 0.14D (- 0.14D for left) in the local
Y direction
- Z of hip joint center is Z of ASIS – 0.3D
Mass properties of body segments are calculated using anatomical information from de
Leva’s anthropometry model, which provides segment mass as a percentage of total body
mass, segment center of mass as a percentage of segment length, and radii of gyration for
frontal plane, sagittal plane, and longitudinal axis [197].
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The joint axes and degrees of freedom are based on International Society of
Biomechanics standards [134], [198], [199]. The joint rotation sequence, (described
earlier) follows the pattern of the axis with major muscle movement first, then the lesser
two axes. For example, with the pelvis coordinate system as Z=yaw, Y=pitch, X=roll, the
knee rotation sequence follows: Y (flexion), X (abduction), Z (internal rotation).
Once the program acquires all of the necessary input information, the HBM is fit
to the subject. The model is scaled to the size of the subject, and forward kinematic
equations are used to calculate the coordinates of the markers. The skeleton pose is then
found by a process known as global optimization [200], where the entire model as a
whole is best fit to the markers. This function is a nonlinear least-squares equation, which
essentially minimizes the difference between the measured marker pose and the desired
pose of the model. This is an iterative solution process, where the function runs
repeatedly until the solution with the smallest difference is found. Since this process
occurs for each frame, the computation occurs quickly, at the speed of 1.0ms to run in
real-time [130].
An important factor in every calculation is filtering. Since the raw data undergoes
many calculations, unfiltered noise will become amplified through the process. A secondorder Butterworth filter, for both force plate and marker data is used. Since filtering
causes a time delay, choosing the appropriate filter was a balance between power and
speed to allow for continual real time processing [130].
4.2.2.2 Marker Model
This study used the full-body marker model, which uses 47 markers to discern the
body segments and the kinematic degrees of freedom (see Figure 11 and Table IV). The
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goal for a good marker model is to use the least amount of markers while providing the
cameras with enough information to accurately assign the location of each body segment.
Three markers are the minimum for each body segment to properly discern the x, y, and z
coordinates. This eliminates the possibility of two markers rotating about an axis that
produces no translation, therefore appearing to have no motion. It is also advantageous to
have markers that may apply to more than one segment to minimize the total number of
markers. For example, the lateral epicondyle is part of both the femur and shank
segments [1].

Figure 11 – Full-body marker model [1].
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Table IV – Anatomical marker placement key [1]
Marker
Name
LASIS
RASIS
LPSIS
RPSIS
LGTRO
RGTRO
LLEK
RLEK
LLM
RLM
LTOE
RTOE
LSHO
RSHO
LLEE
RLEE
LMEE
RMEE
LLW
RLW
LMW
RMW
XYPH
C7

Anatomical Marker Location

Marker
Name
Left anterior superior iliac spine
THEAD
Right anterior superior iliac spine
RHEAD
Left posterior superior iliac spine
LHEAD
Right posterior superior iliac spine SACR
Left greater trochanter
T10
Right greater trochanter
NAVE
Left lateral epicondyle of knee
STRN
Right lateral epicondyle of knee
LDELT
Left lateral malleolus
RDELT
Right lateral malleolus
LFIN
Left head of first toe
RFIN
Right head of first toe
BBAC
Left acromion process of shoulder FLTHI
Right acromion process of FRTHI
shoulder
Left lateral epicondyle of elbow
LATI
Right lateral epicondyle of elbow
RATI
Left medial epicondyle of elbow
LHEE
Right medial epicondyle of elbow RHEE
Left lateral epicondyle of wrist
LMT5
Right lateral epicondyle of wrist
RMT5
Left medial wrist
LFRM
Right medial wrist
RFRM
Xyphoid process
FHEAD
Vertebra C7

Anatomical Marker Location
Top of head
Right side of head
Left side of head
Sacrum
Vertebra T10
Navel
Sternum
Left deltoid of the humerus
Right deltoid of the humerus
Left 3rd metacarpal
Right 3rd metacarpal
Center of right scapula
Left mid-thigh
Right lateral mid-thigh
Left lateral tibialis anterior
Right lateral tibialis anterior
Left posterior of heel
Right posterior of heel
Left head of 5th metatarsal
Right head of 5th metatarsal
Left mid forearm
Right mid forearm
Forehead

4.2.2.3 Outcome Variables
The CAREN lab provides vast amounts of data from its different integrated
systems. The Vicon motion capture system yields marker coordinates in an x, y, z
coordinate system, the forces and moments in the x, y, and z directions, and the video
cameras record video from two different angles. These inputs are all integrated into the
D-Flow software, which can take the raw data and compile more meaningful metrics for
various applications. In addition to D-Flow, the CAREN system is equipped with the Gait
Offline Analysis Tool, which manipulates saved data from an HBM session for further
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analysis. The metrics exported from the Gait Offline Analysis Tool include: marker
coordinates, joint angles, stance phase, stride length and treadmill speed. This data was
further processed, if necessary, and organized with a custom Matlab program to yield the
biomechanical outcome variables listed below in Table V.
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Table V – Biomechanical outcome measures
Variable
Speed
Cadence
Step Length
Stance Phase

Ankle ROM

Knee ROM

Hip ROM

Arm swing path length

Normalized Jerk
Trunk Rotation ROM

Pelvic Tilt ROM

Pelvic Obliquity ROM

Pelvic rotation ROM

Description
Measured by self-selected speed algorithm
Number of heel strikes per minute (both left and right)
Meters from heel strike to subsequent heel strike on each leg
separately
Percent of gait cycle (defined as heel strike to subsequent heel
strike on same leg) in which the foot makes contact with the
ground. The remainder of the cycle is considered swing phase
Ankle flexion/extension (plantar flexion/dorsiflexion) along
the X axis in the sagittal plane, measured as maximum
flexion minus minimum flexion per gait cycle
Knee flexion/extension, along the X axis in the sagittal plane,
measured as maximum flexion minus minimum flexion per
gait cycle
Hip flexion/extension, along the X axis in the sagittal plane,
measured as maximum flexion minus minimum flexion per
gait cycle
The 3-dimensional path length per arm swing cycle, which is
measured from the maximum anterior position in the –Z
direction to the subsequent maximum anterior position of the
finger marker, which is placed approximately in the center of
the back of the hand
Jerk is calculated from the arm swing path length per arm
swing cycle (defined above), normalized by time and distance
Rotation about the Y axis in the transverse plane, left twist is
a positive value, right twist is negative, measured as
maximum rotation value minus the minimum rotation value
per gait cycle
Rotation about the X axis in the sagittal plane, anterior tilt
(ASIS markers lower than PSIS markers) is a positive value,
posterior tilt (PSIS markers lower than ASIS markers) is a
negative value, measured as maximum rotation value minus
the minimum rotation value per gait cycle
Rotation about the Z axis, in the frontal plane. Left drop/right
lift is a positive value, left lift/right drop is negative.
Measured as maximum angle minus minimum angle per gait
cycle
Measured similarly to trunk rotation

56

4.2.3 Cognitive Tasks
4.2.3.1 N-Back
The N-back task is a working memory test where a list of stimuli is presented at
regular intervals, and the participant is asked to recall the stimulus presented N times
prior in the list [201]. This test has been used in various populations, for various purposes
[201]–[204]. Commonly seen versions include a string of numbers, shapes, or an object
placement in space [205]. For this study, the 2-back version of the test was used, which
entails the subject to recall whether the letter currently presented is the same (“yes”) or
different (“no”) from the letter presented two prior in the string. The score is calculated as
number of correct responses.
4.2.3.2 Serial Subtractions
The serial sevens subtractions test was first developed in 1942 by Dr. Max
Hayman M.D. as a time efficient and cost effective cognitive test to assess mental
capacity of cognitively challenged populations. The original design of the test consists of
starting with the number 100, subtracting seven, subtracting seven from the calculated
difference, and continually repeating these subtractions until the number two is reached.
The score is the completion time, as well as the number of correct answers over the
number of total answers [206]. This test uses working memory and information
processing, which are both related to executive functioning [11]. Modifications are often
made to the test, such as using a different starting number [108], different subtrahend
[108], [116], allowing a limited time for test completion [108], or scoring by counting
total number correct [109]. This study used a version of this test where a random starting
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number between 200 and 400 was used, and calculations subtracting seven occurred for
60 seconds. The number of correct responses only was used to calculate the score.
4.2.3.3 Verbal Fluency
The verbal fluency test entails producing as many words as one can think of in a
specific category in a set time frame. Versions of the test vary by category, such as
“animals”, “colors”, or “words that begin with the letter F”, and response, written or oral.
The test is scored as number of correct, unique answers in one minute (oral) or five
minutes (written) [86]. The verbal fluency test examines the executive function of
selective attention, internal response generation and self-monitoring [207]. The
Controlled Word Association Test (COWAT) is a common, standardized version of
verbal fluency. Three letters are given to the participant, allowed 60 seconds of response
time per letter, and the score is combined from all three letter responses. Currently, there
are two sets of letters that are considered equivalent and utilized in the COWAT [86].
Borkowski et al. have studied each letter of the alphabet individually to find equivalency
in terms of possible answers [208], which broadens testing options. The letters S, T, F,
and P were used for this study.
4.3 Data Analysis
The spatiotemporal gait parameters compared between the PDE and PDC groups
include: walking speed (m/s), cadence (steps/min), normalized step length (% of leg
length) and stance phase (% of gait cycle). The kinematic gait parameters include: ankle,
knee and hip ROM (degrees), ROM of trunk rotation in the transverse plane (trunk
rotation) (degrees) and ROM of the pelvis in the sagittal, frontal, transverse and planes
(pelvic tilt, pelvic obliquity, pelvic rotation) (degrees). The upper extremity gait
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parameters include: normalized arm swing path length (PL) (% of arm length), and
normalized jerk (NJ). Walking speed was selected at the beginning of each testing
session, and remained constant for the remainder of the session across all walking and
DT conditions. Cadence, step length, stance phase, and joint ROM were all calculated
and reported through the Gait Offline Analysis Tool. A custom-built Matlab program
provided additional data processing. Cadence was calculated by total number of steps
taken for both feet combined, divided by the total time. Step length and stance phase
were calculated per gait cycle, then the average was taken over all gait cycles completed
per trial. Joint ROM was calculated from the joint angles reported per time stamp by
finding the maximum and minimum angles per gait cycle to calculate the total ROM, and
taking the average ROM over all gait cycles per trial. Further description of
biomechanical outcome measures can be found in Table K.
Arm swing outcomes (PL and NJ) used 3-dimensional coordinate position data.
First, the arm swing was calculated relative to the pelvis to account for body
displacement within the motion capture volume. The pelvis center was found by taking
the average of the 3-dimensional coordinates of the four iliac crest markers, which was
then subtracted from the lateral wrist markers. The arm swing metrics were reported as
average per arm swing cycle (one cycle defined as the maximum anterior position to the
subsequent maximum anterior position). Path length computed from the left and right
wrist markers using the ‘arclength’ Matlab function [184], describes the 3-dimensional
distance traveled per arm swing. Path length was also used to calculate jerk, a measure to
describe smoothness of movement.
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Jerk, or smoothness of movement, is defined as the rate of change in acceleration.
The methods for calculating arm swing jerk have been publish in previous work [115].
Using position data, the third derivative was taken to obtain jerk. Mathematical noise
increases with each derivative calculation [209]; therefore, a jerk measurement derived
from position data would be noisier from a jerk measurement derived from accelerometer
data. To assess this discrepancy, trials were completed on the CAREN system to compare
accelerometer-derived jerk and position-data-derived jerk. An individual walked at a
constant speed with an iPod attached to the wrist, with a marker attached to the iPod
itself. The jerk calculated from the position data was compared to the jerk calculated
from the acceleration data from the iPod.
Before comparison, the appropriate filtration was found for both the
accelerometer and position data. The accelerometer data from the iPod was filtered using
a second-order Butterworth filter. The cutoff frequency was found using residual analysis
[2]. This process involves comparing the difference between the raw and filtered signal,
called the residual, across a range of cutoff frequencies. The residual is calculated as
follows (N = number of sample points in time, 𝑥𝑖 = raw data at ith sample, 𝑥̂𝑖 = filtered
data at ith sample, see Figure 12):

1

𝑅(𝑓𝑐 ) = √𝑁 ∑𝑁
̂𝑖 )2 [2]
𝑖=1(𝑥𝑖 − 𝑥
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Figure 12 – Residual analysis [Winter 1990], along the y-axis is the residual R(fc)
calculated from increasing cutoff values (fc, along the x-axis), line de = estimate of noise
residual, line bc = estimate of noise distortion and allowed noise, point a = projection of
tangent line from line de at 0Hz , horizontal projection from point a to the residual curve
creates point b, vertical projection of point b lands at the desired cutoff frequency, f1c.

Once the appropriate filter was applied to the accelerometer data, the derivative
was taken to obtain the jerk measure from the accelerometer data (accelerometer-to-jerk).
Next, second-order Butterworth filters with a range of cutoff frequencies were applied to
the position data, then the third derivative was taken (position-to-jerk):

𝑓𝑖′′′ ≈

𝑓1+2 − 2𝑓𝑖+1 + 2𝑓𝑖−1 − 𝑓𝑖−2
2ℎ3

The results of varying cutoff frequencies of the position-to-jerk data were then
compared to the accelerometer-to-jerk data. Jerk by time plots were visually inspected, as
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well as resulting values (see Figure 13). Keeping to the closest multiple of 0.05 Hz, a
frequency cutoff value of 1.25 Hz was selected.
A

B

C

Figure 13 – Comparing arm swing jerk plots between accelerometer derived and position
derived data in anterior-posterior (z) direction. A: accelerometer derived jerk plot, B:
position data derived jerk without additional filter, C: position data derived jerk with 2nd
order Butterworth filter using 1.25 Hz cutoff frequency.

Jerk can be employed and reported in a variety of ways [210], depending on the
application. For this study, normalized jerk (NJ) was chosen [211] to account for the
variability between subjects’ arm movements (T = total time, L = total length).
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𝑇5
𝑁𝐽 = 0.5 ∫ [𝑥⃛(𝑡) + 𝑦⃛(𝑡) + 𝑧⃛(𝑡) ] 𝑑𝑡( 2 )
𝐿
𝑡1
2

2
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All outcome measures were calculated for the left and right side separately, and
further categorized into the more and less affected side based on severity of symptom
presentation determined by UPDRS scores or self-report. Due to the lack of significant
differences between the more and less affected sides, results were collapsed across sides.
To test group differences at baseline, each outcome measure during the ST condition was
compared between the PDE, PDC and HC groups. Kruskal-Wallis ANOVA was
performed between the three subject groups, and Mann-Whitney U tests were performed
between the PDE and PDC groups, and the PDE and HC groups.
To assess differences in change over time/intervention, the delta (Δ = EOT –
baseline) was computed for all outcome measures (PDE and PDC groups only), and
compared between the PDE and PDC groups to assess changes due to the exercise
intervention. Shapiro-Wilk normality tests revealed non-normality for over 50% of Δ
outcome data, therefore Mann-Whitney tests were conducted for each Δ outcome
measure, for each task condition (ST, BACK, SUB, VERB) between the PDE and PDC
groups. Comparison between the PDE group at baseline and the HC group, and the PDE
group at EOT and the HC group were completed using Mann-Whitney tests.
Cognitive test scores were analyzed for changes in cognition (Δ under ST
conditions) and changes due to dual-tasking. In efforts to use cognitive test scores in the
manner that clinicians do to assess cognitive changes [212], dual-task difference (DTD)
was used. Dual-task difference is simply the raw change in score from ST to DT
conditions. Changes due to dual-tasking were also analyzed for all gait outcome measures
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for both the PDE and PDC groups. Friedman’s ANOVA’s were performed first between
all four tasks (ST and DT’s) in a testing session, and if significance was found,
subsequent pairwise Wilcoxon Signed Rank Tests were performed between the ST and
each DT condition. The significance level was set at α=0.05. All statistical analysis was
performed using OriginPro 2017 statistical software (OriginLab Corporation,
Northampton, Massachusetts). Due to data integrity standards, some outcome measures
have a decreased sample size. Particular outcomes that were deemed inaccurate and
unrecoverable were omitted. Sample size for each outcome measure is listed in
Appendix C.
4.4 Results
Comparing the PDE and PDC groups at baseline and the HC group, there were
significant differences in speed, stance phase, step length, hip ROM, PL, and pelvic
obliquity ROM under ST conditions.
Subsequent comparisons of the PDE and PDC groups showed no significant
differences at baseline in any outcome measure under ST conditions.
4.4.1 Change from baseline to EOT (Δ)
Of the spatiotemporal measures, significant differences in the change from
baseline to EOT between the PDE and PDC groups existed for all measures. Results are
listed in Appendix D. The change in self-selected walking speed from baseline to EOT in
the PDE group (median = 0.11 m/s) was significantly greater than the Δ walking speed
for the PDC group (median = -0.05 m/s), U = 146.5, p < 0.05 (See Figure 14). The Δ
cadence was only significant for the ST condition, with a significantly larger increase for
the PDE group (median = 4.52 steps/min) compared to the PDC group (median = -3.00
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steps/min), U = 142, p < 0.05. The Δ stance phase was significant for the ST, SUB and
VERB conditions, with the PDE group showing significant decreases compared to the
PDC, and Δ step length showed significant increases for the PDE group compared to the
PDC group for all task conditions. Of the lower extremity kinematic measures, there were
significant differences in the change from baseline to EOT between the PDE and PDC
groups for the ankle, knee and hip joint ROM (See Figure 15). The Δ ankle ROM for the
BACK condition was significantly larger for the PDE group (median = 1.52) compared to
the PDC group (median = -2.13), U = 153, p < 0.05. The Δ knee ROM was significantly
larger than the PDC group for both the BACK and SUB conditions, and the Δ hip was
significantly larger than the PDC group for all task conditions. Of the trunk and pelvis
ROM measures, only Δ trunk rotation ROM showed significance, with the PDE group
(median = 1.35) resulting in a significantly larger increase than the PDC group (median =
-0.16), U = 135, p < 0.05. Of the arm swing measures, no significant differences were
observed in changes in PL; however, the Δ NJ was significantly larger for the PDE group
compared to the PDC group for the ST, BACK and SUB conditions (See Figure 15).
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Figure 14 – Average speed for Parkinson’s disease exercise (PDE) and Parkinson’s
disease control (PDC) groups at baseline and EOT.
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Figure 15 – Median results of change from baseline to end of trial (Δ) for lower
extremity measures comparing Parkinson’s disease exercise (PDE) and Parkinson’s
disease control (PDC) groups. ST, single-task; BACK, N-back dual-task; SUB, serial-7
subtraction dual-task; VERB, verbal fluency dual-task; *, significant difference between
PDE and PDC groups at p < 0.05 level.
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Figure 16 – A) Results of change from baseline to end of trial (Δ) for normalized path
length (PL), B) median results of change from baseline to end of trial (Δ) for normalized
jerk (NJ). PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease control
group; ST, single-task; BACK, N-back dual-task; SUB, serial-7 subtraction dual-task;
VERB, verbal fluency dual-task; *, significant difference between PDE and PDC groups
at p < 0.05 level.

4.4.2 Comparison between PDE and HC
Comparison between PDE at baseline and the HC group showed that the PDE
group displayed significant gait deficits in speed, cadence, stance phase, step length, knee
ROM, pelvic obliquity ROM, pelvic rotation ROM, PL and NJ. When comparing the
PDE group at EOT with the HC group, the PDE group maintained gait deficits in pelvic
obliquity ROM, PL and NJ, but was no longer significantly different in speed, cadence,
stance phase, step length, knee ROM and pelvic rotation ROM (see Figure 17). Results
listed in Appendix E.

67

HC (25%~75%)
PDE (25%~75%)
Min~Max
Median Line

Gait Speed
2.0

*

HC (25%~75%)
PDE (25%~75%)
Min~Max
Median Line

Cadence

*

150

steps per minute

m/s

1.5

1.0

100

0.5
50

0.0

HC

PDE

HC

Baseline

PDE

HC

EOT

Stance Phase

HC (25%~75%)
PDE (25%~75%)
Min~Max
Median Line

74

PDE

HC

Baseline

PDE
EOT

HC (25%~75%)
PDE (25%~75%)
Min~Max
Median Line

Step Length
*
100

72
80

70

% leg length

% gait cycle

*

68

60

40

66
20

64
HC

PDE

HC

Baseline

0

PDE

HC

Knee ROM

PDE

*

PDE
EOT

Pelvic Rotation ROM

HC (25%~75%)
PDE (25%~75%)
Min~Max
Median Line

80

HC

Baseline

EOT

30

HC (25%~75%)
PDE (25%~75%)
Min~Max
Median Line

*

60

degrees

degrees

20

10

40

0
20

HC

PDE
Baseline

HC

PDE

HC

EOT

PDE
Baseline

HC

PDE
EOT

Figure 17 – Median results for comparison between the Parkinson’s disease exercise
group (PDE) and healthy control (HC) group. ST, single-task; BACK, N-back dual-task;
SUB, serial-7 subtraction dual-task; VERB, verbal fluency dual-task; *, significant
difference between PDE and HC groups at p < 0.05 level.
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4.4.3 Change in Variability
There were no significant differences between the PDE and PDC groups in Δ
variability for any outcome measure.
4.4.4 Cognitive Test Scores
There were no significant differences between the PDE and PDC groups in Δ
under ST conditions for any of the cognitive tasks.
4.4.5 Changes from ST to DT
Differences in outcome measures between ST and DT conditions were present for
both the PDE and PDC groups. The PDE group experienced DT declines in cadence,
knee ROM and pelvic tilt ROM. The PDC group experienced DT changes in cadence, hip
ROM, PL, trunk rotation ROM, pelvic tilt ROM, and pelvic obliquity ROM, results listed
in Appendix F.
4.5 Discussion
As anticipated, significant differences were observed between all three subject
groups. Subsequent group comparisons between the PDE and PDC groups resulted in an
overall lack of significance between the two groups, and comparisons between the PDE
and HC groups resulted in significant differences, with the PDE group showing gait
declines across most outcome measures. These results are consistent with previous
studies [17], [46], [213].
To investigate changes in gait parameters in PD due to a high-intensity cycling
intervention compared to changes observed in PD over the same time frame without a
prescribed intervention, the Δ was compared between the PDE and PDC groups. The
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comparison of the Δ for PDE and PDC groups was intended to account for inter-subject
variability and possible improvements due to learning effects. However, in this particular
sample group, the PDC group showed no significant change from baseline to EOT.
Not only did the self-selected speed increase significantly for the PDE group
compared to the PDC group, but the 0.11 m/s median increase also falls in the minimal
clinically important difference range (0.10 – 0.20 m/s) [214]. Under the ST condition,
significant improvements were seen in seven out of 13 biomechanical outcome measures.
All spatiotemporal measures showed significant improvement, as well as hip and trunk
rotation ROM, and NJ. Improvement in lower extremity gait function in those with PD
due to an exercise intervention is consistent with previous studies [125], [136], [158],
[159], [194], [215]. Although upper extremity gait function is less critical for a successful
walking motion and rarely investigated in interventional studies, it can be an indicator of
global deficit [54], [124]. Similar to different biomechanical measures describing the
quality of walking gait for the lower extremities, PL and NJ demonstrate differences in
arm swing function.
Although differences in PL did not reach statistical significance, there was a
significant decrease in NJ in the PDE group compared to the PDC group, indicating an
increase in smoothness of movement. It has been suggested that declines in arm swing
are related to rigidity [216], a symptom affecting all aspects of gait. Therefore, positive
changes observed in arm swing may be linked to changes in gait. Furthermore, these
changes may be centrally mediated, suggested by the lack of participation of the upper
extremity in the intervention [28]–[30], [150]. Crenna et al. suggest that projections from
the basal ganglia to the cervical spinal cord are regarded as less evolutionarily crucial as
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compared to projections to lumbo-sacral segments, explaining the early appearance of
arm swing deficits in PD, as well as its limited improvements due to dopaminergic
therapy or deep brain stimulation [58]. Since prioritization of gait function lies with the
lower limb first, changes seen in the upper limb may signify a more robust change.
Interestingly, the PDE group in Figure 16a shows a collection of individuals reaching
higher levels of improvement in PL than what is seen in the PDC group. These results in
addition to improvements in NJ, suggest further investigation of the mechanics of arm
swing as a result of exercise intervention and its role on overall motor function.
Improvements in gait function due to high-intensity exercise are encouraging in
terms of supplementing current treatment methods for PD symptom relief. Understanding
how exercise effects gait in objective detail will contribute to the understanding of
specific aspects of gait improvement, and how it impacts movements of daily activities.
Successful walking is important for individuals to carry out daily tasks safely and
effectively. It is well understood that individuals with PD experience increased gait
declines under DT conditions, which poses another obstacle for successful walking.
Therefore, the presence of significant improvements in gait measures under DT
conditions suggests sustained motor improvement, and results that are clinically and
practically relevant to the everyday lives of those struggling with PD. All DT conditions
showed improvements in spatiotemporal and lower extremity joint kinematics,
demonstrating the ability to sustain benefits from exercise across additional cognitive
loading across various aspects of executive function.
Changes in arm swing not only manifest with the presence of PD [54], [55], but it
can also change under conditions of increased cognitive load [115], [124]. This
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connection of a relatively passive movement during gait to neurological function might
serve as a marker for centrally mediated changes [28]–[30], [150]. Declines in
smoothness of arm swing movement in PD has been shown to worsen under DT
conditions, suggesting cognitive loading impacts movement quality [115] as well as
magnitude. Similar to lower extremity measures, NJ has shown improvement across ST
and two of the DT conditions, suggesting that centrally mediated improvements remain
under cognitively taxing conditions.
Due to the significant findings comparing the PDE and PDC group, the results
were expanded to compare the PDE group to the HC group. Changes in walking speed
typically includes proportional changes in overall biomechanics, such as joint angles and
step length [217]. Therefore, increases in biomechanical measures are to be expected as
walking speed increases. With PD however, the gait patterns are not simply characteristic
of slowed gait. The combination of decreased speed with little to no change in cadence,
decreased joint ROM, increased stance phase and decreased step length indicate a
trademark pattern of walking known as “shuffle gait” [213]. Compared to the HC group,
the PDE group at baseline walked significantly slower, spent a larger portion of the gait
cycle with both feet on the ground in stance phase, and had smaller step lengths. This
indicates that the PDE group took smaller, quicker steps than healthy peers, and had less
overall knee ROM.
The change in gait characteristics exhibited by the PDE group were not only
significant compared to the PDC group, but they were also particularly interesting when
compared to healthy older adults. As mentioned, the PDE group demonstrated typical PD
related gait deficits compared to the HC group. At EOT, the PDE groups not only
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improved, but they also were no longer significantly different from the HC group in gait
speed, cadence, stance phase, step length and knee ROM. This is similar to the effects of
dopaminergic therapy for some studies [11], [12], and shows greater improvement than
others [46], [47]. Exercise studies with animal models have shown increased
neurotrophic factors, such as brain- and glial-derived neurotrophic factors (BDNF and
GDNF), contributing to neuroprotection of existing nigrostriatal pathways, and
regeneration of dopaminergic axons [218]. Detailed structural and chemical neural
changes due to exercise are difficult to obtain and corroborate with animal model results;
however, peripheral BDNF has been shown in increase in human exercise studies [218].
The results of this study mimicking the effects of dopaminergic medication while “off”
medication may be explained by these previous findings. Arm swing function, however,
remains significantly worse in PD than HC, even after intervention. Further studies are
warranted to investigate arm swing as it relates to alternative treatments for PD.
The results of this study coincide with previous studies regarding decreased motor
function under DT conditions in PD [109]–[111], [119]. Despite the regularity of the
speed of the treadmill potentially providing external cuing and regulating walking
patterns [219], significant changes occurred. Interestingly, cadence increased
significantly in all three DT conditions for the PDE group at baseline and EOT, even
though the speed maintained the same from ST to DT. The PDC group also experienced
significant increases in cadence at EOT testing. Step length and stance phase also
followed patterns of decline under DT conditions, however these measures did not reach
significance. In previous studies, gait declines under DT conditions include changes in
speed [111], [114], [220]–[222], which cannot decipher whether the declines are due to
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general slowed walking speed, or gait characteristics are actually changing. The results
found in this study suggest that changes in gait performance from ST to DT conditions
signifies a change in gait pattern, independent of gait speed. Changes in upper extremity
independent of speed, under DT conditions has been found in previous studies [115],
[124], and now the decoupling of lower extremity measures adds greater understanding to
the breakdown of the interconnected rhythmic nature of walking when cognitive loading
in increased.
The CV outcome measures did not result in any significant differences. The
predicted cause of this finding is similar to the DTC findings. The constant speed of the
treadmill may have regulated gait movements, therefore altering any potential changes in
variability [219].
The results of the cognitive test scores were contradictory to the hypothesis
predicting increases in cognitive function, as well as changes in dual-tasking strategies. A
“posture second” DT strategy is common with PD, where individuals prioritize the
cognitive task over the motor task. The safety features of the CAREN system may have
contributed to a feeling of security, therefore allowing subjects to adhere to a posture
second strategy.
CHAPTER V: Conclusion
Gait and balance measures have shown improvements after a high-intensity
cycling exercise intervention in PD. Balance recovery after a perturbation has shown a
decrease in COPex, suggesting less compensatory movements and, potentially, improved
balance control. Walking also showed marked improvements in speed and quality of gait
movement under both ST and DT conditions.
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The ability to recover from destabilization is essential for avoiding falls and
injury. People with PD have an increased fall risk compared to healthy older adults [77],
therefore efforts to decrease the risk of falling and resultant injuries are particularly
important in the PD population. Since dopaminergic therapy cannot be relied upon to aid
in balance improvement [47], [68], other therapies and interventions need to be
investigated for their potentials in improving dynamic postural stability. The results from
this study point towards positive effects from exercise intervention, suggesting that the
neural effects of exercise impact non-dopaminergic pathways. The effects of Lewy
bodies on PD symptoms is not as prominently studied as the effects from basal ganglia
dysfunction, yet it may point to discrepancies between dopaminergic therapies and
remaining symptoms [40]. Brain-derived neurotrophic factor increases in the central
nervous system after aerobic exercise, and has a positive effect on synaptic plasticity
[223]. Although research investigating the effects of exercise on Lewy bodies in the brain
is sparse [224], the results from this study suggest further investigation.
Spatiotemporal outcome measures are common to describe biomechanical data;
however, jerk has shown to provide additional information about movement quality,
especially in PD [115], [225]. Jerk has shown to differentiate PD patients from healthy
controls in static balance studies [226]–[228], and with the addition of marker data to a
perturbation study on the CAREN system, this knowledge could be expanded to include
jerk under dynamic balance conditions.
In addition to balance recovery, healthy gait function is also important for fall
avoidance. Safe, successful gait not only minimizes injury, it can increase self-efficacy
for physical activity in older adults and encourages continual physical activity [229].
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Conscious gait strategies have proven successful in improving gait in PD such as external
cueing and thoughtful stepping [230]; however, everyday situations do not always lend
themselves to gait focused thoughts while traversing. The ability to complete a cognitive
task while walking is crucial to daily activities, even tasks as simple as remembering a
room number while walking through a large building. Compensatory gait strategies that
require additional cognitive resources risk competing with the cognitive tasks commonly
encountered in real world situations, leaving either the cognitive task or gait function to
suffer. Parkinson’s disease medications provide symptom relief and help deter gait
declines; however, these declines may still be present with dopaminergic medication
[11], [46], [47]. The abstract nature of stationary cycling translating to balance and upper
extremity improvements suggests neural changes worth further exploration. The ease of
execution and positive side effects of high-intensity cycling make for an attractive
supplemental PD treatment option.
High-intensity exercise interventions that demonstrate improved function in “off”
medication conditions may potentially have an additive affect to levodopa/carbidopa
medications, as suggested from increases in motor functions while “on” medication, seen
in previous studies [158], [159], [194]. The potential structural improvements in
nigrostriatal projections from an exercise intervention [218] may increase motor function
improvements when coupled with additional dopamine via medication. To better
understand the effects of intervention on specific balance recovery and gait parameters,
future studies are needed that include analysis under both “off” and “on” conditions.
The resources necessary for detailed motion capture analysis are not attainable
nor feasible for a wide population of individuals. Efforts are being made to enable small,
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portable technology to provide specific measures that can infer gait function [231]–[233]
which can expand the usage of gait function as a clinical tool. As the understanding of the
implications of arm swing develops, it has the potential to provide valuable information
for gait analysis [115], [124] in a concise manner. The results from this study suggest that
further investigation of arm swing as it relates to gait, cognition, and interventions is
warranted.
Limitations exist within this project. The PD population for both exercise and
control groups were comprised of mild to moderately affected individuals, and it is
unclear if a more severe population would demonstrate different results from an exercise
intervention. Information concerning the presence of clinical cognitive impairment was
not collected, which may have shown a relationship in different cognitive test abilities.
During balance data collection with the Time to Stable application, some participants
took a step to catch their balance, or grabbed onto the handrails. It was instructed to avoid
these movements and return to their original position as quickly as possible if this does
occur; however, suppressing these automatic responses was difficult for some
individuals. Steps or handrail grabs were recorded manually, however no correction or
data segregation was made based on these actions. Future studies could investigate
potential differences in trials with catching actions versus those without. Marker
occlusion of some degree was present in most gait trials. Much of this was corrected
within the HBM, or was fixed manually via post processing; however, some data was
lost. Most of the marker occlusion was a result of clothing coverage. Future studies
should provide motion capture suits to ensure the best methods of data collection.
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APPENDIX A

Time to Stable outcome data

Group
PDE
PDC
HC

Baseline
Acceleration Level (m/s2)
0.25
0.5
1.0
3.04
4.58 a
4.30 a
4.30
5.98
5.05 a
2.91
3.72
4.84

EOT
Acceleration Level (m/s2)
0.25
0.5
1.0
2.73
3.17 c
3.44 a
3.65
3.71
4.61

Outcome
ΔTTS

PDE
Acceleration Level (m/s2)
0.25
0.5
1.0
-0.15
-1.61
-0.64

PDC
Acceleration Level (m/s2)
0.25
0.5
1.0
-0.70
-1.03
-0.43

Median results in seconds. PDE, Parkinson’s disease exercise group; PDC, Parkinson’s
disease control group; HC, healthy control group; ΔTTS, change in Time to Stable from
baseline to end of treatment; xa, significant difference compared to 0.25 of same session;
xb, significant difference compared to 0.5 of same session; xc, significant difference
compared to baseline, significant at 0.05 level.
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APPENDIX B

Center of pressure excursion data

EOT

PDC
Baseline

EOT

1.79 (0.33)

1.67 (0.36)

1.63 (0.22)

1.64 (0.38)

0.5 m/s2

2.03 (0.40)

1.69 (0.36)

1.69 (0.29)

1.64 (0.37)

1.0 m/s2

1.92 (0.33)

1.84 (0.44)

1.78 (0.26)

1.61 (0.28)

Acceleration
Level
0.25 m/s2

PDE
Baseline

HC

1.88
(0.29)
1.95
(0.25)
2.13
(0.17)

Mean (SD) results in meters. PDE, Parkinson’s disease exercise group; PDC, Parkinson’s
disease control group; HC, healthy control group; EOT, end of treatment.
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APPENDIX C

Sample size of biomechanical outcome measures
Δ

BACK

PDE
SUB

VERB

ST

PDC
BACK
SUB

VERB

ST

HC
BACK SUB

VERB

ST
Gait speed
(m/s)
Cadence
(steps/min)
Stance Phase
(% gait cycle)
Normalized
step length
(step/leg length)
Ankle ROM
(degrees)
Knee ROM
(degrees)
Hip ROM
(degrees)
Trunk rotation
ROM (degrees)
Pelvic tilt ROM
(degrees)
Pelvic obliquity
ROM (degrees)
Pelvic rotation
ROM (degrees)
Normalized PL
(PL/arm length)
Normalized
jerk

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

12

13

13

13

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

13

13

13

13

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

14

13

13

13

13

13

13

13

13

14

14

14

14

13

13

13

13

13

13

13

13

14

14

14

14

Right and left sides were collapsed when applicable, out of 14 participants maximum.
PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease control group; HC,
healthy control group; PL, normalized path length; NJ, normalized jerk; ROM, range of
motion; CV, coefficient of variation; ST, single-task; BACK, N-back dual-task; SUB,
serial-7 subtraction dual-task; VERB, verbal fluency dual-task.
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APPENDIX D

Change from baseline to EOT outcome measures
Δ
Gait speed (m/s)
Cadence (steps/min)
Stance Phase (% gait
cycle)
Step length (% leg
length)
Ankle ROM (degrees)
Knee ROM (degrees)
Hip ROM (degrees)
Trunk rotation ROM
(degrees)
Pelvic tilt ROM
(degrees)
Pelvic obliquity ROM
(degrees)
Pelvic rotation ROM
(degrees)
PL (% arm length)
NJ
CV Stance phase
CV Step length
CV Ankle ROM
CV Knee ROM
CV Hip Rom
CV PL

PDE
SUB

ST
0.11
4.52
-1.69

BACK
3.05
-1.27

3.00
-1.58

11.49

7.73

0.65
1.19
3.04
1.35

VERB

PDC
SUB

BACK

3.64
-1.43

ST
-0.05 *
-3.00 *
0.46 *

VERB

-0.51
0.04

-0.52
-0.10 *

-2.01
0.36 *

7.13

8.50

-0.19 *

-3.24 *

-2.01 *

-1.31 *

1.52
1.93
2.03
2.15

1.36
1.94
2.56
1.66

1.87
2.09
2.56
1.79

-0.52
-1.05
-0.44 *
-0.16 *

-2.13 *
-1.80 *
-0.23 *
-0.23

-1.94
-1.51 *
-0.51 *
-0.73

-2.26
-0.77
-0.02 *
0.25

-0.27

-0.60

-0.24

-0.17

2.07

2.65

1.99

2.61

-0.37

-0.20

-0.01

-0.03

-0.12

-0.81

-1.02

-0.55

0.79

0.61

0.36

0.46

1.06

0.11

0.44

0.96

9.12
144.98
0.02
-0.07
-0.80
-0.16
-1.21
-2.07

-0.56
-83.23

1.92
-151.91

-0.01
-128.00

-0.42
-1.60
-0.42
-0.26
-0.93
1.88

-0.51
-1.30
0.44
-0.29
-0.36
-1.13

-1.11
214.81
*
-3.60
-0.23
-0.99
-0.45
-1.04
1.28

-4.00
157.84
*
-0.50
0.32
-0.01
0.09
-0.46
-2.60

-5.43
206.94

-0.47
-1.41
-0.75
-0.40
-0.96
0.28

-1.97
297.33
*
-0.21
-0.10
0.68
0.64
0.23
-1.04

-0.18
0.18
0.26
0.32
0.15
-0.21

Median results. PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease
control group; HC, healthy control group; PL, normalized path length; NJ, normalized
jerk; ROM, range of motion; CV, coefficient of variation; ST, single-task; BACK, Nback dual-task; SUB, serial-7 subtraction dual-task; VERB, verbal fluency dual-task; *,
significant difference between PDE and PDC groups at p < 0.05 level.
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APPENDIX E

Comparison between Parkinson’s disease exercise and healthy control groups
Outcome measure
Speed (m/s)
Cadence (steps/min)
Stance Phase (% gait cycle)
Step length (% leg length)
Ankle ROM (degrees)
Knee ROM (degrees)
Hip ROM (degrees)
Trunk rotation ROM (degrees)
Pelvic tilt ROM (degrees)
Pelvic obliquity ROM (degrees)
Pelvic rotation ROM (degrees)
PL (% arm length)
NJ

PDE - baseline
0.875
99.01
67.85
61.10
28.46
54.35
37.45
12.02
4.09
6.46
6.50
43.50
1815.81

PDE - EOT
1.03
103.00
66.09
74.90
28.73
57.13
39.98
13.24
4.08
6.65
7.65
54.39
1786.51

HC
1.25 a
109.99 a
65.54 a
78.12 a
31.37
60.49 a
42.38
17.23
4.95
9.11 a,b
9.05 a
91.62 a,b
1402.74 a,b

PDE, Parkinson’s disease exercise group, PDC, Parkinson’s disease control group; HC,
healthy control group; PL, normalized path length; NJ, normalized jerk; ROM, range of
motion; xa, significant difference compared to PDE at baseline; xb, indicates significant
difference compared to PDE at EOT, significance at p < 0.05 level.
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APPENDIX F

Dual-task effects, PDE and PDC groups
PDE

Cadence (steps/min)
Stance Phase (% gait
cycle)
Step length (% leg
length)
Ankle ROM
(degrees)
Knee ROM (degrees)
Hip ROM (degrees)
Trunk rotation ROM
(degrees)
Pelvic tilt ROM
(degrees)
Pelvic obliquity
ROM (degrees)
Pelvic rotation ROM
(degrees)
PL (% arm length)
NJ

ST

Baseline
BACK
SUB

VERB

ST

BACK

EOT
SUB

99.01
67.85

104.48 *
67.23

101.51 *
67.32

104.01 *
67.35

103.00
66.09

108.50 *
66.16

105.00 *
65.79

109.00 *
65.96

61.10

58.81

59.66

58.09

74.86

70.00

72.87

70.90

28.46

27.46

27.59

28.11

28.73

29.17

28.48

28.80

54.35
37.45
11.20

53.14 *
36.82
9.78 *

53.06
38.26
10.53

52.30
37.42
10.17 *

57.13
39.98
13.24

56.10 *
38.48
12.50

57.45
39.06
12.21

55.84 *
38.13
12.25

4.09

4.27

4.45

4.12

4.08

3.59

3.89

3.96

6.46

5.89

6.43

5.83

6.65

6.57

7.13

6.70

6.50

5.95

6.29

5.66

7.65

7.18

7.51

7.33

43.50
1815.81

29.94
1816.62

30.45
1975.04

28.25
2045.72

54.39
1786.51

43.82
1739.88

41.43
1945.70

38.62
1849.99

ST

Baseline
BACK
SUB

VERB

ST

BACK

106.98
65.97

107.49
65.98

105.48
66.68

106.98
65.98

98.46
66.30

104.48 *
66.14

100.49
66.21

102.49
66.03

60.55

61.86

61.00

63.02

53.49

50.90

52.08

54.96

28.17

28.00

29.15

28.50

26.94

24.70

26.22

25.75

55.51
35.66
11.70

55.96
34.59
9.98

55.80
33.84
9.67

55.97
34.13
10.79

55.11
34.80
10.68

53.81
33.75 *
8.61

54.63
32.75 *
10.26

54.21
33.27 *
10.04 *

4.89

4.89

5.06

4.89

4.64

4.38

4.38

4.35

5.48

5.58

6.20

5.72

5.07

4.82 *

4.92 *

4.96

5.75

5.50

6.71

6.13

6.95

6.39

6.58

6.52

45.40
1559.58

35.46 *
2089.28

33.71
2303.49

37.87
2366.72

42.03
1744.00

26.91 *
2870.67

26.66
2618.71

26.82 *
2914.70

VERB

PDC

Cadence (steps/min)
Stance Phase (% gait
cycle)
Step length (% leg
length)
Ankle ROM
(degrees)
Knee ROM (degrees)
Hip ROM (degrees)
Trunk rotation ROM
(degrees)
Pelvic tilt ROM
(degrees)
Pelvic obliquity
ROM (degrees)
Pelvic rotation ROM
(degrees)
PL (% arm length)
NJ
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EOT
SUB

VERB

Median results. PDE, Parkinson’s disease exercise group; PDC, Parkinson’s disease
control group; HC, healthy control group; PL, normalized path length; NJ, normalized
jerk; ROM, range of motion; ST, single-task; BACK, N-back dual-task; SUB, serial-7
subtraction dual-task; VERB, verbal fluency dual-task; *, significant difference between
task and ST condition of same session at p < 0.05 level.
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